CMHC - Conference guide 2017 by JOSE WONG AD

This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

WELCOME LETTER

The Cardiometabolic Event of the Year™

Welcome to the 12th Annual Cardiometabolic Health Congress (CMHC)! As the cardiometabolic disease epidemic grows, CMHC continues to lead the educational charge against the enormous clinical and economic challenges, providing a dynamic opportunity to stay informed on the latest developments in the field through a comprehensive and integrated curriculum. Celebrating our 12th year, we are transforming the way we educate to continuously improve our ability to address the prevention, diagnosis, and management of cardiometabolic diseases in the US. Not only is our agenda designed to deliver you the most current innovations and breakthroughs in science, but we’ve also expanded our exhibit hall and enhanced our networking opportunities throughout the conference. Perhaps one of the most exciting new features is CMHC OnDemand, an online CME certified program featuring sessions from the 12th Annual Cardiometabolic Health Congress. Revisit all the presentations you attended during this year’s meeting or participate in sessions you missed. If that’s not enough, visit the CMHC Education Resource Center at www.cardiometabolichealth.org for conference highlights, expert video interviews, online CME activities, eNews, and resources to supplement the live sessions and stay abreast of the most current educational information throughout the year. Enclosed you will find the CMHC Schedule-at-a-Glance as well as information on the Exhibit Hall and Professional Medical Education, Satellite Symposia, the NEW Passport to Prizes, and much more. Should you require assistance during your stay, please do not hesitate to visit the CMHC Registration Desk located on the Second Floor of the Sheraton Boston Hotel or visit the CMHC Booth located at the front of the Exhibit Hall.

Enjoy your stay in Boston!

GEORGE L. BAKRIS, MD Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL

ROBERT H. ECKEL, MD Professor of Medicine Division of Endocrinology, Metabolism and Diabetes Division of Cardiology Professor of Physiology and Biophysics Charles A. Boettcher II Chair in Atherosclerosis Director, T32 in Obesity and Cardiovascular Disease University of Colorado Anschutz Medical Campus Director, Lipid Clinic, University Hospital Aurora, CO

CHRISTIE M. BALLANTYNE, MD JAY S. SKYLER, MD Professor of Medicine, Pediatrics, & Psychology Division of Endocrinology, Diabetes & Metabolism University of Miami Miller School of Medicine Deputy Director for Clinical & Academic Programs Diabetes Research Institute Miami, FL

Professor of Medicine Chief, Section of Cardiovascular Research Chief, Section of Cardiology Department of Medicine, Baylor College of Medicine Director, Center for Cardiovascular Disease Prevention Baylor College of Medicine Methodist DeBakey Heart Center Houston, TX

TABLE OF CONTENTS Welcome Letter

Hours of Operation

Schedule-at-a-Glance

6-7

Expert Speaker Line-Up

8-9

Exhibitor Index

Exhibitors Floorplan

Exhibitor Listings

15 - 27

Professional NON-CME Medical Education

28 - 29

Association & Media Partners

CME/CE Sessions

12th Annual CMHC Accreditation

36 - 37

CMHC - AboutÂ Us

HOURS OF OPERATION

SCIENTIFIC EXHIBIT HALL

MEET THE EXPERTS REGISTRATION HOURS WEDNESDAY OCTOBER 4 9:30AM – 6:00PM

THURSDAY OCTOBER 5 6:15AM – 6:00PM

FRIDAY OCTOBER 6 6:30AM – 6:00PM

SATURDAY OCTOBER 7 6:30AM – 11:30AM

EXHIBIT HALL HOURS THURSDAY OCTOBER 5 10:00AM – 12:00PM 2:00PM – 6:00PM

FRIDAY OCTOBER 6 9:30AM – 12:15PM 2:45PM – 7:00PM

THURSDAY, OCTOBER 5

EXHIBIT HALL

Morning Break; 10:20AM – 11:20AM Christie M. Ballantyne, MD; Deepak L. Bhatt, MD, MPH; Eugene Braunwald, MD

Morning Break; 9:45AM – 10:45AM Stephen Devries, MD; Robert H. Eckel, MD; John P. Foreyt, PhD; Janet M. de Jesus, MS, RD; Barbara Kahn, MD; Frank A.J.L. Scheer, PhD

Afternoon Break; 2:30PM - 3:30PM JoAnn Lindenfeld, MD; Kim K. Birtcher, PharmD; Keith C. Ferdinand, MD; Stanley L. Hazen, MD; Sotirios Tsimikas, MD

BOOK SIGNING THURSDAY • OCTOBER 5 EXHIBIT HALL 10:20AM - 11:20AM

Enhance Your Presence: The Path to Personal Power, Professional Influence, & Business Results by Mark J. Tager, MD and Robert John Hughes

www.CardiometabolicHealth.org

FRIDAY, OCTOBER 6

EXHIBIT HALL

Afternoon Break; 3:00PM – 4:00PM Thomas W. Gardner, MD, MS; C. Ronald Kahn, MD; Davida F. Kruger, MSN, APNBC, BCADM; Wendy S. Lane, MD; Benjamin M. Scirica, MD; Jay S. Skyler, MD

SATURDAY, OCTOBER 7 GRAND BALLROOM FOYER

Morning Break; 9:25AM – 9:55AM George L. Bakris, MD; David A. Calhoun, MD; Virend Somers, MD

W ELCO M E R E CEPT I O N E X H I B I T

H A L L

TH U R S DAY, OCTOBER 5 5: 00PM – 6:00PM

B OSTO N B LOCK PA RTY E X H I B I T

H A L L

FR I DAY, OCTOBER 6 6: 00PM – 7:00PM

www.CardiometabolicHealth.org

e l u d e h Sc

THURSDAY

OCTOBER 5

11:20AM – 1 MAIN KEYN 2:10PM OTE: Gut Microbe s as a Particip ant and Ther Target in Card apeutic iom Stanley L. Haz etabolic Diseases en, MD

at a Glance

WEDNESDAY

OCTOBER 4, 2017

PRE-CONFERENCE “Business of Medicine” Day

10:00 AM – 11:00 AM Constitution Ballroom

Pre-Con BoM Session Patient-Centered Medical Home: A Foundation for Transformation Paul Grundy, MD

11:00 AM – 12:00PM Constitution Ballroom

NON-CME Session The Cardiometabolic Implications of Obesity and Nutritional Strategies for Prevention Frank B. Hu, MD, PhD

12:00 PM – 1:15 PM Constitution Ballroom

NON-CME Session (Lunch) Repatha®(evolocumab): Take the Next Step Yehuda Handelsman, MD 1:20 PM – 2:20 PM

Supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals. 2:30 PM – 3:20 PM

OCTOBER 5, 2017 5:00 PM – 6:00 PM

Constitution Ballroom

BoM Session Expert Discussion: The Psychology Behind Patient Adherence Robert H. Eckel, MD; William H. Polonsky, PhD, CDE

6:00 PM – 7:00 PM

CMHC GENERAL SESSIONS

Grand Ballroom

CME Breakfast Symposium Closing the Gap Created by Clinical Inertia: New Strategies for T2DM Treatment Chair: Robert H. Eckel, MD Presenters: Yehuda Handelsman, MD; Athena Philis-Tsimikas, MD; Julio Rosenstock, MD Session I. DYSLIPIDEMIA, ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE RISK REDUCTION

NON-CME Session (Light Bites) Advancements in the Management of Patients With Type 2 Diabetes: Results From a Large Cardiovascular Outcomes Trial Michael H. Davidson, MD 7:00 PM – 8:00 PM

Constitution Ballroom

NON-CME Session (Dinner) JARDIANCE® (empagliflozin) Tablets: Evolving Clinical Development Raj Deo, MD

OCTOBER 4 1 :20PM – 2:20P Pre-Con Bo

M Session Best Practices: Efficient and Co st-Effective Management of the Authoriza tion Process Pamela B. Mor ris, MD Kim K. Birtche r, PharmD

BoM Featured Session How to Grow Your Revenue By Enhancing Your Presence: In Person, On Camera & Online Mark J. Tager, MD; Robert John Hughes

www.CardiometabolicHealth.org

6:40 AM – 7:55 AM

Grand Ballroom

8:00 AM – 8:05 AM

Grand Ballroom

8:05 AM – 9:20 AM

Grand Ballroom

Opening Remarks Christie M. Ballantyne, MD

FDA Update and Late Breaking Clinical Trials Chair: Christie M. Ballantyne, MD Panelists: Robert H. Eckel, MD; Jay S. Skyler, MD; Keith C. Ferdinand, MD; Deepak Bhatt, MD

WEDNESDAY

3:30 PM – 4:45 PM Constitution Ballroom

Constitution Ballroom

NON-CME Session (Light Bites) Awaken a Transformation in Type 2 Diabetes Management Yehuda Handelsman, MD

Constitution Ballroom

BoM Session Best Practices: Efficient and Cost-Effective Management of the Authorization Process Pamela B. Morris, MD; Kim K. Birtcher, PharmD

THURSDAY

9:20 AM – 10:20 AM Grand Ballroom

Attacking Atherothrombosis: Which Approach to Take? Chair: Christie M. Ballantyne, MD Presenters: Paul M. Ridker, MD; Eugene Braunwald, MD; Marc S. Sabatine, MD 10:20 AM – 11:20 AM Exhibit Hall

Morning Break 11:20 AM– 12:10 PM Grand Ballroom MAIN KEYNOTE: Gut Microbes as a Participant and Therapeutic Target in Cardiometabolic Diseases Stanley L. Hazen, MD 12:15 PM – 1:15 PM Grand Ballroom CME Lunch Symposium

Navigating Updated Guidelines and New Therapies for the Diagnosis and Treatment of Heart Failure Chair: Keith C. Ferdinand, MD Presenters: Clyde W. Yancy, MD; JoAnn Lindenfeld, MD

1:20 PM – 2:00 PM

Grand Ballroom

2:00 PM – 2:30 PM

Grand Ballroom

Mini Session Lp(a) and Promising NEW Targets for Intervention Sotirios Tsimikas, MD Mini Featured Session Treatment for Statin Intolerant Patients with Hypercholesterolemia – Today and Tomorrow Christie M. Ballantyne

This session is supported by an educational grant from Esperion. 2:30 PM - 3:30 PM Exhibit Hall

Afternoon Break

3:30 PM – 4:10 PM

Grand Ballroom

4:10 PM – 5:00 PM

Grand Ballroom

5:00 PM

Grand Ballroom

5:00 PM – 6:00 PM

Exhibit Hall

6:00 PM – 7:00 PM

Constitution Ballroom

7:00 PM – 8:00 PM

Grand Ballroom

Featured Session Topic: Triglycerides and HDL-C: Where Are We Now? Robert H. Eckel, MD Multidisciplinary Case Consults: Challenging Lipid Cases Chair: Christie M. Ballantyne, MD Panelists: Robert H. Eckel, MD; Jay S. Skyler, MD; Kim K. Birtcher, PharmD Closing Remarks Christie M. Ballantyne, MD

Welcome Reception Christie M. Ballantyne, MD; George L. Bakris, MD; Robert H. Eckel, MD; Jay S. Skyler, MD NON-CME Session (Dinner) Clinical Evaluation of Pure EPA Matthew J. Budoff, MD

CME Dinner Symposium Advances in Insulin Therapy: Addressing Provider and Patient Safety Concerns Presenter: Anne L. Peters, MD

FRIBERD6A11Y:25AM–12:15PM OCTO

FRIDAY

y Case Consults: Multidisciplinar ity Management es Lifestyle and Ob abolic Patient in the Cardiomet CHAIR: D Robert H. Eckel, M : TS LIS PANE MD George L. Bakris, yne, MD nt lla Ba . Christie M Jay S. Skyler, MD s, MS, RD Janet M. de Jesu MD ll, ho Sc Johannes

OCTOBER 6, 2017 CMHC GENERAL SESSIONS 6:45AM – 7:45 AM

Constitution Ballroom

CME Breakfast Symposium A Interventional Cardiology Delivered With a Fork Stephen Devries, MD 6:45 AM – 7:45 AM

Grand Ballroom

CME Breakfast Symposium B Ensuring Access to Evidence-Based Therapies in High Risk Special Populations: Statin Intolerance, Racial/Ethnic Minorities and Familial Hypercholesterolemia Keith C. Ferdinand, MD; Catherine Davis Ahmed, MBA Session II: LIFESTYLE MANAGEMENT OF CARDIOVASCULAR DISEASE 8:00 AM – 8:05 AM

Opening Remarks Robert H. Eckel, MD

8:05 AM – 8:55 AM

Grand Ballroom

Featured Session Topic: Novel Mechanisms for the Link Between Obesity and Type 2 Diabetes Barbara Kahn, MD 8:55 AM – 9:45 AM

Grand Ballroom

Cardiometabolic Disorders: Diet Quality, Quantity and Beyond Chair: Robert H. Eckel, MD Presenters: Jamy Ard, MD; Janet M. de Jesus, MS, RD; John P. Foreyt, PhD 9:45 AM – 10:45 AM Exhibit Hall

Morning Break

10:55 AM – 11:25 AM Grand Ballroom

Mini Session Sleep Science: Effect of the Circadian Rhythm on Obesity and CVD Frank A.J.L. Scheer, PhD

11:25 AM – 12:15 PM Grand Ballroom

Multidisciplinary Case Consults: Lifestyle and Obesity Management in the Cardiometabolic Patient Chair: Robert H. Eckel, MD Panelists: George L. Bakris, MD; Christie M. Ballantyne, MD; Jay S. Skyler, MD; Janet M. de Jesus, MS, RD; Johannes Scholl, MD 12:25 PM – 1:40 PM Grand Ballroom

CME Lunch Symposium CV Protection: Is It Achievable in Patients With T2DM? Chair: Jay S. Skyler, MD Presenters: Wendy S. Lane, MD; Robert H. Eckel, MD; Benjamin M. Scirica, MD

SATURDAY OCTOBER 7, 2017

CMHC GENERAL SESSIONS 6:45 AM – 7:45 AM

9:55 AM – 11:05 AM Grand Ballroom

Constitution Ballroom

CME Breakfast Symposium Hyperkalemia Management and Monitoring in High-Risk Patients: Improving Heart Failure Management and Outcomes Chair: George L. Bakris, MD Presenter: JoAnn Lindenfeld, MD

Integrative Topics in Blood Pressure and Hypertension Management Chair: George L. Bakris, MD Presenters: Kumar Sharma, MD; Virend Somers, MD; David G. Harrison, MD

11:05 AM – 11:55 AM Grand Ballroom

Multidisciplinary Case Consults: Challenging Patient Cases in Hypertension, Cardio-Renal, and Heart Failure Chair: George L. Bakris, MD Panelists: Robert H. Eckel, MD; Christie M. Ballantyne, MD; Keith C. Ferdinand, MD; Kumar Sharma, MD; David A. Calhoun, MD

Session III. DIABETES MANAGEMENT

Session IV. HYPERTENSION, CARDIO-RENAL, HEART FAILURE

1:40 PM – 1:45 PM

Grand Ballroom

8:00 AM - 8:05 AM

Grand Ballroom

1:45 PM – 2:25 PM

Grand Ballroom

8:05 AM– 8:55 AM

Grand Ballroom

11:55 AM – 12:25 PM Grand Ballroom

Featured Session New Insights Into Insulin Resistance and How the Body Responds to It C. Ronald Kahn, MD

Featured Session Topic: Metabolomics and Kidney Disease Kumar Sharma, MD

Mini Session Kidney Disease in the Elderly George L. Bakris, MD

8:55 AM – 9:25 AM

Grand Ballroom

12:25 PM – 12:30 PM Grand Ballroom

2:25 PM – 3:00 PM

Grand Ballroom

2017 Guideline Updates: Blood Pressure and Resistant Hypertension David A. Calhoun, MD

3:00 PM – 4:00 PM

Exhibit Hall

Opening Remarks Jay S. Skyler, MD

Reaching Glycemic Goals for Patients with T2DM: Insulin and Non-Insulin Therapies Anne L. Peters, MD Afternoon Break

4:00 PM – 5:15 PM

Grand Ballroom

Managing Microvascular Complications of Diabetes for Improved Patient Outcomes Chair: Jay S. Skyler, MD Presenters: Roy L. Freeman, MD; Thomas Gardner, MD; George L. Bakris, MD 5:15 PM – 5:55 PM

Grand Ballroom

Multidisciplinary Case Consults: Challenging T2DM Patient Cases Chair: Jay S. Skyler, MD Panelists: Robert H. Eckel, MD; George L. Bakris, MD; Christie M. Ballantyne, MD; Davida Kruger, ARNP

Opening Remarks George L. Bakris, MD

9:25 AM – 9:55 AM Grand Ballroom Foyer

Morning Break

Closing Remarks George L. Bakris, MD

SATURDAY

OCTOBER 7 8:05AM – 8 Featured S e :5

5:55 PM – 6:00 PM Grand Ballroom

ss 5AM Topic: Metab ion olomics an d Kidney D Kumar Shar isease ma, MD

Closing Remarks Jay S. Skyler, MD

6:00 PM – 7:00 PM Exhibit Hall

Boston Block Party

7:00 PM – 8:15 PM Constitution Ballroom

NON-CME Session (Dinner) Hypertriglyceridemia & Pancreatitis: Separating Secondary Causes from Familial Chylomicronemia Syndrome (FCS) Paul D. Rosenblit, MD, PHD, FACE, FNLA

www.CardiometabolicHealth.org

CMHC

CHAIRPERSONS

EXPERT SPEAKER Line-Up

Christie M. Ballantyne, MD

George L. Bakris, MD

Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL

Robert H. Eckel, MD

Jay S. Skyler, MD

Professor of Medicine Division of Endocrinology, Metabolism and Diabetes Division of Cardiology Professor of Physiology and Biophysics Charles A. Boettcher II Chair in Atherosclerosis Director, T32 in Obesity and Cardiovascular Disease University of Colorado Anschutz Medical Campus Director, Lipid Clinic, University Hospital Aurora, CO

Please see pages 36-37 to view all faculty listings and disclosures.

Catherine Davis Ahmed, MBA Vice President, Policy and Outreach The FH Foundation Pasadena, CA

Jamy D. Ard, MD Assoc. Professor, Div of Public Health Sciences Dept. of Epidemiology & Prevention Wake Forest School of Medicine Co-Director, Weight Management Center Medical Director, Medical Weight Loss Program Wake Forest Baptist Health Winston-Salem, NC

David A. Calhoun, MD Professor of Medicine Medical Director, Vascular Biology and Hypertension Program University of Alabama at Birmingham Birmingham, AL

Janet M. de Jesus, MS, RD Program Officer, Implementation Science Center for Translation Research and Implementation Science (CTRIS) National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, MD

Roy Freeman, MD Professor of Neurology Harvard Medical School Director, Center for Autonomic and Peripheral Nerve Disorders Beth Israel Deaconess Medical Center Boston, MA

Thomas W. Gardner, MD, MS Professor of Ophthalmology and Visual Sciences and Molecular and Integrative Physiology University of Michigan Kellogg Eye Center Ann Arbor, MI

www.CardiometabolicHealth.org

Professor of Medicine, Pediatrics, & Psychology Division of Endocrinology, Diabetes & Metabolism University of Miami Miller School of Medicine Deputy Director for Clinical & Academic Programs Diabetes Research Institute Miami, FL

New Senior Planning Committee

Deepak L. Bhatt, MD, MPH Professor of Medicine Harvard Medical School Executive Director Interventional Cardiovascular Programs Brigham and Women’s Hospital Heart and Vascular Center Boston, MA

Stephen Devries, MD, FACC Executive Director Gaples Institute for Integrative Cardiology Deerfield, IL

Paul Grundy, MD, MPH, FACOEM, FACPM Chief Medical Officer and Director, Healthcare Transformation IBM Global Healthcare Life Science Industry Prof. University of Utah School of Medicine Department of Family and Preventive Medicine Hopewell Junction, NY

Kim K. Birtcher, PharmD Clinical Professor University of Houston College of Pharmacy Houston, TX

Keith C. Ferdinand, MD, FACC, FAHA Professor of Medicine Tulane University School of Medicine Tulane Heart and Vascular Institute New Orleans, LA

Yehuda Handelsman, MD Medical Director and Principal Investigator Metabolic Institute of America Tarzana, CA

Eugene Braunwald, MD Hersey Distinguished Professor of the Theory and Practice of Physic Harvard Medical School Chairman, TIMI Study Group Brigham and Women’s Hospital Boston, MA

John P. Foreyt, PhD Professor, Department of Medicine Baylor College of Medicine Houston, TX

David G. Harrison, MD, FACC, FAHA Director, Division of Clinical Pharmacology Professor, Department of Medicine Betty and Jack Bailey Chair in Cardiology Professor, Department of Pharmacology Professor, Department of Molecular Physiology & Biophysics Vanderbilt University Medical Center Nashville, TN

Stanley L. Hazen, MD, PhD Chair, Department of Cellular & Molecular Medicine Vice Chair, Translational Research, Lerner Research Institute Section Head, Preventive Cardiology & Rehabilitation Director, Center for Cardiovascular Diagnostics & Prevention Cleveland Clinic Cleveland, OH

Wendy S. Lane, MD Clinical Endocrinologist Director of Clinical Research Mountain Diabetes and Endocrine Center Asheville, NC

William H. Polonsky, PhD, CDE President, Behavioral Diabetes Institute Associate Clinical Professor University of California San Diego, CA

Johannes Scholl, MD Facharzt für Innere Medizin, Ernährungsmedizin, Sportmedizin Dr. Scholl Prevention First GmbH Frankfurt am Main Germany

Sotirios Tsimikas, MD Professor of Medicine Director of Vascular Medicine University of California San Diego La Jolla, CA

Robert John Hughes

Barbara Kahn, MD George R. Minot Professor of Medicine Harvard Medical School Vice Chair, Department of Medicine Beth Israel Deaconess Medical Center Division of Endocrinology, Diabetes and Metabolism Boston, MA

ChangeWell Inc. San Diego, CA

JoAnn Lindenfeld, MD Director, Heart Failure and Transplant Professor of Medicine Vanderbilt University School of Medicine Nashville, TN

Paul M. Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital Boston, MA

Benjamin M. Scirica, MD, MPH Associate Professor of Medicine, Harvard Medical School Associate Physician, Brigham and Women’s Hospital Senior Investigator, TIMI Study Group Brigham and Women’s Hospital/TIMI Study Group Boston, MA

Clyde W. Yancy, MD, MSc, MACP Magerstadt Professor of Medicine Professor of Medical Social Sciences Chief, Div. of Cardiology, Northwestern Univ. Feinberg School of Medicine Assoc. Director, Bluhm Cardiovascular Institute Northwestern Memorial Hospital Chicago, IL

Pamela B. Morris, MD Director, Seinsheimer Cardiovascular Health Program Co-Director, Women’s Heart Care Medical University of South Carolina Charleston, SC

Julio Rosenstock, MD Director, Dallas Diabetes and Endocrine Center Clinical Professor of Medicine University of Texas Southwestern Medical Center Dallas, TX

Kumar Sharma, MD Professor of Medicine Director, Institute of Metabolomic Medicine Center for Renal Translational Medicine UC San Diego Health Sciences San Diego, CA

C. Ronald Kahn, MD

Davida F. Kruger, MSN, APNBC, BCADM

Mary K. Iacocca Professor of Medicine Harvard Medical School Chief Academic Officer Joslin Diabetes Center Boston, MA

Certified Nurse Practitioner Henry Ford Health System Division of Endocrinology, Diabetes, Bone and Mineral Disease Detroit, MI

Athena PhilisTsimikas, MD

Anne L. Peters, MD

Corporate Vice President Scripps Whittier Diabetes Institute San Diego, CA

Professor, Keck School of Medicine Director, Clinical Diabetes Programs University of Southern California Los Angeles, CA

Frank A.J.L. Scheer, PhD

Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine Brigham and Women’s Hospital Professor of Medicine Harvard Medical School Boston, MA

Associate Professor of Medicine, Harvard Medical School Director, Medical Chronobiology Program, Brigham & Women’s Hospital Division of Sleep and Circadian Disorders Departments of Medicine and Neurology Brigham & Women’s Hospital Boston, MA

Mark J. Tager, MD

Virend K. Somers, MD, PhD Alice Sheets Marriott Professor of Medicine Mayo Clinic Rochester, MN

CEO ChangeWell Inc. San Diego, CA

EXPERT SPEAKER

Line-Up

www.CardiometabolicHealth.org

EXHIBITOR INDEX Company name

Booth #

HOURS OF OPERATION OCT

OCT

THURSDAY

FRIDAY

10:00AM – 12:00PM 2:00PM – 6:00PM

9:30AM – 12:15PM 2:45PM – 7:00PM

Company name

Booth #

Advanced Clinical Products

519

Human Metabolome Technologies

320

Aegerion Pharmaceuticals

513

Ideal Protein of America

314

Akcea Therapeutics

308

Janssen Pharamceuticals, Inc.

518

Allergan 527

Kastle Therapeutics

326

Amarin Pharma, Inc.

421

Kyoui 324

American Board of Clinical Lipidology

220

Kowa Pharmaceuticals America, Inc.

305

Amgen 504

Merck & Co., Inc.

413

Arbor Pharmaceutical, LLC

Metagenics 418

312

Boehringer Ingelheim Pharmaceuticals, Inc / Lilly USA 313

Novartis Pharmaceuticals Corporation Inc.

520

Canada RNA Biochemical Inc.

321

Novo Nordisk® Inc.

204

ChangeWell Training Academy

218

Regeneron-Sanofi

521

Cinsulin 213

Relypsa 525

Cleveland HeartLab

208

Seca 318

Corcept Therapeutics

419

Spectracell Laboratories

Diem Labs

215

Tenstim 225

Genova Diagnostics

209

The Core Group

412

Great Plains Laboratory

319

UNIsource Health

205

G.S. Innovations

424

www.CardiometabolicHealth.org

304

EXHIBITOR FLOOR PLAN

CMHC Lit Table

227 Tenstim

American Board of Clinical Lipidology (ABCL)

ChangeWell Training Academy

Diem Labs LLC

Relypsa

Human

Canada

Technologies

Biochemical

Ideal Protein

Amarin

Corcept

Plains Lab

BoehringerLilly USA

Cinsulin

Allergan

KYOUI

seca

Regeneron -Sanofi

Pharma

Advanced Clinical Products

The Core Group

Aegerion Pharmaceuticals

Arbor Pharma

POSTER PRESENTATION AREA Cleveland Heart Lab

Novo Nordisk

EXHIBIT HALL

G.S. Innovations

Kastle Therapeutics

Therapeutics

UNIsource Health

SpectraCell Lab

Pharma

Amgen

ENTRANCE ON 3RD FLOOR OF SHERATON HOTEL

www.CardiometabolicHealth.org

DOWNLOAD

THE 2017 MEETING APP

CMHC 2017

Enhance your educational experience

FEATURES INCLUDE: •

Conference slides available

•

Browse sessions, abstracts, speakers, exhibitors and build your itinerary

•

Locate exhibitor booths and session rooms

•

Participate in social media conversations and engage with other CMHC attendees

To access the web version of the CMHC App visit: http s : / / e ve n t m o b i. co m / cm h c2 0 1 7 / 12

www.CardiometabolicHealth.org

Learn more about Repatha® at CMHC - visit Booth 504 For adults with clinical ASCVD on maximally tolerated statin therapy as an adjunct to diet1

HELP YOUR PATIENTS

ESCAPE HIGH LDL-C ADD REPATHA® AND MAXIMIZE LDL-C REDUCTION Repatha® every 2 weeks + statin delivered

77 REDUCTION

UP TO

% ADDITIONAL LDL-C compared to placebo + statin1,2 Results from a 12-week study in patients with ASCVD. At week 12, LDL-C was reduced 63% to 77% (mean 71%) with Repatha® 140 mg every 2 weeks + statin more than with placebo + statin. Maximum-dose statins used were atorvastatin 80 mg, rosuvastatin 40 mg, and simvastatin 40 mg.1,2 ASCVD = atherosclerotic cardiovascular disease.

Indication • Repatha® is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (CVD), who require additional lowering of low density lipoprotein cholesterol (LDL-C). • The effect of Repatha® on cardiovascular morbidity and mortality has been published. Inclusion of the results in the approved labeling is under evaluation with the FDA. Important Safety Information • Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®. • Allergic reactions: Hypersensitivity reactions (e.g. rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve. • Adverse reactions: The most common adverse reactions (> 5% of Repatha®-treated patients and more common than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions. In a 52-week trial, adverse reactions led to discontinuation of treatment in 2.2% of Repatha®-treated patients and 1% of placebo-treated patients. The most common adverse reaction that led to Repatha® treatment discontinuation and occurred at a rate greater than placebo was myalgia (0.3% versus 0% for Repatha® and placebo, respectively). • Adverse reactions from a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site reactions in Repatha®-treated patients and placebo-treated patients were 0.1% and 0%, respectively. © 2017 Amgen Inc. All rights reserved. Not for reproduction. USA-145-049910 06-17

Allergic reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%). Neurocognitive events were reported in less than or equal to 0.2% in Repatha®-treated and placebo-treated patients. In a pool of placebo- and active-controlled trials, as well as open-label extension studies that followed them, a total of 1,988 patients treated with Repatha® had at least one LDL-C value < 25 mg/dL. Changes to background lipid-altering therapy were not made in response to low LDL-C values, and Repatha® dosing was not modified or interrupted on this basis. Although adverse consequences of very low LDL-C were not identified in these trials, the long-term effects of very low levels of LDL-C induced by Repatha® are unknown. Musculoskeletal adverse reactions were reported in 14.3% of Repatha®-treated patients and 12.8% of placebo-treated patients. The most common adverse reactions that occurred at a rate greater than placebo were back pain (3.2% versus 2.9% for Repatha® and placebo, respectively), arthralgia (2.3% versus 2.2%), and myalgia (2.0% versus 1.8%). • Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with Repatha®. Please see Brief Summary of full Prescribing Information on adjacent page. References: 1. Repatha® (evolocumab) Prescribing Information, Amgen. 2. Data on file, Amgen; 2015.

REPATHA® (evolocumab) BRIEF SUMMARY OF PRESCRIBING INFORMATION Please see package insert for full Prescribing Information

treated patients and 1% of placebo-treated patients. The most common adverse reaction that led to REPATHA treatment discontinuation and occurred at a rate greater than placebo was myalgia (0.3% versus 0% for REPATHA and placebo, respectively). Table 1. Adverse Reactions Occurring in Greater than or Equal to 3% of REPATHA-treated Patients and More Frequently than with Placebo in Study 2

Nasopharyngitis Upper respiratory tract infection Influenza

1. INDICATIONS AND USAGE 1.1 Primary Hyperlipidemia REPATHA is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD), who require additional lowering of low density lipoprotein cholesterol (LDL-C). 1.2 Homozygous Familial Hypercholesterolemia REPATHA is indicated as an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C. 1.3 Limitations of Use The effect of REPATHA on cardiovascular morbidity and mortality has not been determined. 4. CONTRAINDICATIONS REPATHA is contraindicated in patients with a history of a serious hypersensitivity reaction to REPATHA [see Warnings and Precautions (5.1)]. 5. WARNINGS AND PRECAUTIONS 5.1 Allergic Reactions Hypersensitivity reactions (e.g., rash, urticaria) have been reported in patients treated with REPATHA, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with REPATHA, treat according to the standard of care, and monitor until signs and symptoms resolve. 6. ADVERSE REACTIONS The following adverse reactions are also discussed in other sections of the label: • Allergic Reactions [see Warnings and Precautions (5.1)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In a 52-week, double-blind, randomized, placebocontrolled trial (Study 2), 599 patients received 420 mg of REPATHA subcutaneously once monthly [see Clinical Studies (14.1)]. The mean age was 56 years (range: 22 to 75 years), 23% were older than 65 years, 52% women, 80% White, 8% Black, 6% Asian, and 6% Hispanic. Adverse reactions reported in at least 3% of REPATHA-treated patients, and more frequently than in placebo-treated patients in Study 2, are shown in Table 1. Adverse reactions led to discontinuation of treatment in 2.2% of REPATHA-

9.3

6.3

7.5

Back pain

5.6

6.2

Injection site reactions†

5.0

5.7

Cough

3.6

4.5

Urinary tract infection

3.6

4.5

Sinusitis

3.0

4.2

Headache

3.6

4.0

Myalgia

3.0

4.0

Dizziness

2.6

3.7

Musculoskeletal pain

3.0

3.3

Hypertension

2.3

3.2

Diarrhea

2.6

3.0

Gastroenteritis

2.0

3.0

includes erythema, pain, bruising

Adverse Reactions in Seven Pooled 12-Week Controlled Trials In seven pooled 12-week, double-blind, randomized, placebo-controlled trials, 993 patients received 140 mg of REPATHA subcutaneously every 2 weeks and 1059 patients received 420 mg of REPATHA subcutaneously monthly. The mean age was 57 years (range: 18 to 80 years), 29% were older than 65 years, 49% women, 85% White, 5% Black, 9% Asian, and 5% Hispanic. Adverse reactions reported in at least 1% of REPATHA-treated patients, and more frequently than in placebo-treated patients, are shown in Table 2. Table 2. Adverse Reactions Occurring in Greater than 1% of REPATHA-treated Patients and More Frequently than with Placebo in Pooled 12-Week Studies

Nasopharyngitis

REPATHA is not indicated for use in patients without familial hypercholesterolemia or atherosclerotic CVD [see Indications and Usage (1.1)].

Adverse Reactions in a 52-Week Controlled Trial

6.3

†

Adverse Reactions in Patients with Primary Hyperlipidemia and in Patients with Heterozygous Familial Hypercholesterolemia

The data described below reflect exposure to REPATHA in 8 placebo-controlled trials that included 2651 patients treated with REPATHA, including 557 exposed for 6 months and 515 exposed for 1 year (median treatment duration of 12 weeks). The mean age of the population was 57 years, 49% of the population were women, 85% White, 6% Black, 8% Asians, and 2% other races.

Placebo REPATHA (N=302) (N=599) % % 9.6 10.5

Placebo REPATHA† (N=1224) (N=2052) % % 3.9 4.0

Back pain Upper respiratory tract infection Arthralgia

2.2

2.3

2.0

2.1

1.6

1.8

Nausea

1.2

1.8

Fatigue

1.0

1.6

Muscle spasms

1.2

1.3

Urinary tract infection

1.2

1.3

Cough

0.7

1.2

Influenza Contusion

1.1 0.5

1.2 1.0

140 mg every 2 weeks and 420 mg once monthly combined

†

Adverse Reactions in Eight Pooled Controlled Trials (Seven 12-Week Trials and One 52-Week Trial) The adverse reactions described below are from a pool of the 52-week trial (Study 2) and seven 12-week trials. The mean and median exposure durations of REPATHA in this pool of eight trials were 20 weeks and 12 weeks, respectively. Local Injection Site Reactions Injection site reactions occurred in 3.2% and 3.0% of REPATHA-treated and placebo-treated patients, respectively. The most common injection site

www.CardiometabolicHealth.org

reactions were erythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site reactions in REPATHAtreated patients and placebo-treated patients were 0.1% and 0%, respectively. Allergic Reactions Allergic reactions occurred in 5.1% and 4.7% of REPATHA-treated and placebo-treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for REPATHA and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%). Neurocognitive Events In placebo-controlled trials, neurocognitive events were reported in less than or equal to 0.2% in REPATHA-treated and placebo-treated patients. Low LDL-C Levels In a pool of placebo- and active-controlled trials, as well as open-label extension studies that followed them, a total of 1988 patients treated with REPATHA had at least one LDL-C value < 25 mg/dL. Changes to background lipid-altering therapy were not made in response to low LDL-C values, and REPATHA dosing was not modified or interrupted on this basis. Although adverse consequences of very low LDL-C were not identified in these trials, the longterm effects of very low levels of LDL-C induced by REPATHA are unknown. Musculoskeletal Events Musculoskeletal adverse reactions were reported in 14.3% of REPATHA-treated patients and 12.8% of placebo-treated patients. The most common adverse reactions that occurred at a rate greater than placebo were back pain (3.2% versus 2.9% for REPATHA and placebo, respectively), arthralgia (2.3% versus 2.2%), and myalgia (2.0% versus 1.8%). Adverse Reactions in Patients with Homozygous Familial Hypercholesterolemia In a 12-week, double-blind, randomized, placebocontrolled trial of 49 patients with HoFH (Study 4), 33 patients received 420 mg of REPATHA subcutaneously once monthly [see Clinical Studies (14.3)]. The mean age was 31 years (range: 13 to 57 years), 49% were women, 90% White, 4% Asian, and 6% other. The adverse reactions that occurred in at least two (6.1%) REPATHA-treated patients, and more frequently than in placebo-treated patients, included: • Upper respiratory tract infection (9.1% versus 6.3%) • Influenza (9.1% versus 0%) • Gastroenteritis (6.1% versus 0%) • Nasopharyngitis (6.1% versus 0%) 6.2 Immunogenicity As with all therapeutic proteins, there is potential for immunogenicity. The immunogenicity of REPATHA has been evaluated using an electrochemiluminescent bridging screening immunoassay for the detection of binding anti-drug antibodies. For patients whose sera tested positive in the screening immunoassay, an in vitro biological assay was performed to detect neutralizing antibodies. In a pool of placebo- and active-controlled clinical trials, 0.1% of patients treated with at least one dose of REPATHA tested positive for binding antibody development. Patients whose sera tested positive for binding antibodies were further evaluated for neutralizing antibodies; none of the patients tested positive for neutralizing antibodies. There was no evidence that the presence of anti-drug binding antibodies impacted the pharmacokinetic profile, clinical response, or safety of REPATHA, but the long-term consequences of continuing REPATHA treatment in the presence of anti-drug binding antibodies are unknown. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to REPATHA with the incidence of antibodies to other products may be misleading.

REPATHA were ≥ 65 years old and 171 were 8. USE IN SPECIFIC POPULATIONS ≥ 75 years old. No overall differences in safety 8.1 Pregnancy or effectiveness were observed between these Risk Summary There are no data available on use of REPATHA patients and younger patients, and other reported in pregnant women to inform a drug-associated clinical experience has not identified differences in risk. In animal reproduction studies, there were no responses between the elderly and younger patients, effects on pregnancy or neonatal/infant development but greater sensitivity of some older individuals when monkeys were subcutaneously administered cannot be ruled out. evolocumab from organogenesis through parturition 8.6 Renal Impairment at dose exposures up to 12 times the exposure at No dose adjustment is needed in patients with mild the maximum recommended human dose of 420 to moderate renal impairment. No data are available mg every month. In a similar study with another in patients with severe renal impairment [see Clinical drug in the PCSK9 inhibitor antibody class, humoral Pharmacology (12.3)]. immune suppression was observed in infant monkeys exposed to that drug in utero at all doses. 8.7 Hepatic Impairment The exposures where immune suppression occurred No dose adjustment is needed in patients with in infant monkeys were greater than those expected mild to moderate hepatic impairment (Childclinically. No assessment for immune suppression Pugh A or B). No data are available in patients was conducted with evolocumab in infant monkeys. with severe hepatic impairment [see Clinical Measurable evolocumab serum concentrations Pharmacology (12.3)]. were observed in the infant monkeys at birth at 13. NONCLINICAL TOXICOLOGY comparable levels to maternal serum, indicating that 13.1 Carcinogenesis, Mutagenesis, Impairment evolocumab, like other IgG antibodies, crosses the of Fertility placental barrier. FDA’s experience with monoclonal The carcinogenic potential of evolocumab antibodies in humans indicates that they are unlikely to was evaluated in a lifetime study conducted cross the placenta in the first trimester; however, they in the hamster at dose levels of 10, 30, and are likely to cross the placenta in increasing amounts 100 mg/kg administered every 2 weeks. There in the second and third trimester. Consider the benefits were no evolocumab-related tumors at the highest and risks of REPATHA and possible risks to the fetus dose at systemic exposures up to 38- and 15-fold before prescribing REPATHA to pregnant women. the recommended human doses of 140 mg every In the U.S. general population, the estimated 2 weeks and 420 mg once monthly, respectively, background risk of major birth defects and based on plasma AUC. The mutagenic potential miscarriage in clinically recognized pregnancies is of evolocumab has not been evaluated; however, monoclonal antibodies are not expected to alter DNA 2-4% and 15-20%, respectively. or chromosomes. Data There were no adverse effects on fertility Animal Data In cynomolgus monkeys, no effects on embryo-fetal (including estrous cycling, sperm analysis, mating or postnatal development (up to 6 months of age) performance, and embryonic development) at were observed when evolocumab was dosed during the highest dose in a fertility and early embryonic organogenesis to parturition at 50 mg/kg once every developmental toxicology study in hamsters when 2 weeks by the subcutaneous route at exposures evolocumab was subcutaneously administered at 30- and 12-fold the recommended human doses of 10, 30, and 100 mg/kg every 2 weeks. The highest 140 mg every 2 weeks and 420 mg once monthly, dose tested corresponds to systemic exposures respectively, based on plasma AUC. No test of up to 30- and 12-fold the recommended human humoral immunity in infant monkeys was conducted doses of 140 mg every 2 weeks and 420 mg once monthly, respectively, based on plasma AUC. In with evolocumab. addition, there were no adverse evolocumab-related 8.2 Lactation effects on surrogate markers of fertility (reproductive Risk Summary organ histopathology, menstrual cycling, or sperm There is no information regarding the presence parameters) in a 6-month chronic toxicology of evolocumab in human milk, the effects on the study in sexually mature monkeys subcutaneously breastfed infant, or the effects on milk production. administered evolocumab at 3, 30, and 300 mg/kg The development and health benefits of breastfeeding once weekly. The highest dose tested corresponds to should be considered along with the mother’s clinical 744- and 300-fold the recommended human doses need for REPATHA and any potential adverse effects of 140 mg every 2 weeks and 420 mg once monthly, on the breastfed infant from REPATHA or from the respectively, based on plasma AUC. underlying maternal condition. Human IgG is present in human milk, but published data suggest that 13.2 Animal Toxicology and/or Pharmacology breast milk antibodies do not enter the neonatal and During a 3-month toxicology study of 10 and 100 mg/kg once every 2 weeks evolocumab in infant circulation in substantial amounts. combination with 5 mg/kg once daily rosuvastatin in 8.4 Pediatric Use adult monkeys, there were no effects of evolocumab The safety and effectiveness of REPATHA in on the humoral immune response to keyhole limpet combination with diet and other LDL-C-lowering hemocyanin (KLH) after 1 to 2 months exposure. therapies in adolescents with HoFH who require The highest dose tested corresponds to exposures additional lowering of LDL-C were established based 54- and 21-fold higher than the recommended on data from a 12-week, placebo-controlled trial human doses of 140 mg every 2 weeks and 420 mg that included 10 adolescents (ages 13 to 17 years once monthly, respectively, based on plasma AUC. old) with HoFH [see Clinical Studies (14.3)]. In this Similarly, there were no effects of evolocumab on trial, 7 adolescents received REPATHA 420 mg the humoral immune response to KLH (after 3 to 4 subcutaneously once monthly and 3 adolescents months exposure) in a 6-month study in cynomolgus received placebo. The effect of REPATHA on LDL-C monkeys at dose levels up to 300 mg/kg once was generally similar to that observed among adult weekly evolocumab corresponding to exposures patients with HoFH. Including experience from open- 744- and 300-fold greater than the recommended label, uncontrolled studies, a total of 14 adolescents human doses of 140 mg every 2 weeks and 420 mg with HoFH have been treated with REPATHA, with a once monthly, respectively, based on plasma AUC. median exposure duration of 9 months. The safety ® profile of REPATHA in these adolescents was similar This Brief Summary is based on the REPATHA Prescribing Information v3, 07/16 to that described for adult patients with HoFH. The safety and effectiveness of REPATHA have not been established in pediatric patients with HoFH who are younger than 13 years old. REPATHA® (evolocumab) The safety and effectiveness of REPATHA have not Manufactured by: Amgen Inc. been established in pediatric patients with primary One Amgen Center Drive hyperlipidemia or HeFH. Thousand Oaks, California 91320-1799 U.S. License Number 1080 8.5 Geriatric Use In controlled studies, 1420 patients treated with Patent: http://pat.amgen.com/repatha/ © 2017 Amgen Inc. All rights reserved. Not for reproduction. v3 07/16

EXHIBITOR LISTINGS AMARIN PHARMA, INC.

ADVANCED CLINICAL PRODUCTS

AKCEA THERAPEUTICS

BOOTH #519

BOOTH #308

3230 BETHANY LANE STE 9 ELLICOTT CITY, MD 21042 P: 240-285-7484 www.advancedclinicalproducts.com

55 CAMBRIDGE PARKWAY SUITE 100 CAMBRIDGE, MA 02142 P: 617-207-0297 www.akceatx.com

1430 ROUTE 206, SUITE 200 BEDMINSTER, NJ 07921 P: 908-719-1315 www.amarincorp.com

We focus on selling clinically relevant, revenue driven, diagnostic equipment to physicians across the United States. We sell all types of general medical equipment, tables, etc. at our partner; Medical Device Depot (www.medicaldevicedepot.com). Our customers satisfaction is the most important focus for us, whether it is a large hospital group, or a single physician practice.

Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc., is a development and commercialization company focused on transforming serious cardiometabolic lipid disorders. Akcea’s portfolio spans multiple targets and disease states, including both rare and more common lipid disorders, using advanced RNA-targeted antisense therapeutics.

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information visit www.amarincorp.com.

AEGERION PHARMACEUTICALS

ALLERGAN

AMERICAN BOARD OF CLINICAL LIPIDOLOGY

BOOTH #513

to Prizes

BOOTH #527

ONE MAIN STREET, STE 800 CAMBRIDGE, MA 02142 P: 617-500-7867 www.aegerion.com

400 INTERPACE PARKWAY PARSIPPANY, NJ 07054 P: 862-261-7000 www.allergan.com

Aegerion Pharmaceuticals is a biopharmaceutical company that develops and commercializes innovative therapies for patients with debilitating rare diseases. Aegerion has a diverse portfolio and is an indirect subsidiary of Novelion Therapeutics, a company dedicated to developing new standards of care for individuals living with rare diseases. Novelion seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

BOOTH #421

BOOTH #220 6816 SOUTHPOINT PKWY STE 1000 JACKSONVILLE, FL 32216 P: 904-674-0752 www.lipidboard.org The mission of the ABCL is to reduce morbidity and mortality from dyslipidemia and related diseases by evaluating and certifying the training and knowledge of physicians in the field of Clinical Lipidology. To help achieve that mission and to promote the interests of Diplomates and their patients, the ABCL established and maintains a rigorous and clinically valid certification process to assure clinical competency by physicians in the field of Clinical Lipidology. Of even greater importance, this certification process helps achieve good patient outcomes by promoting a standard of excellence in clinical care.

www.CardiometabolicHealth.org

EXHIBITOR LISTINGS AMGEN

pharmaceutical company currently focused on the cardiovascular, hospital, neuroscience, and pediatric markets. Visit www.arborpharma.com or send email inquiries to info@arborpharma.com Arbor Pharmaceuticals, LLC

BOOTH #504 ONE AMGEN CENTER DR THOUSAND OAKS, CA 91320 P: 805-447-4568 www.amgen.com Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC / LILLY USA

ARBOR PHARMACEUTICAL, LLC

CANADA RNA BIOCHEMICAL INC.

BOOTH #312

to Prizes

6 CONCOURSE PARKWAY, STE 1800 ATLANTA, GA 30328 P: 678-334-2420 www.arborpharma.com Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty

www.CardiometabolicHealth.org

the most potent and best researched oral fibrinolytic agent hands-down; CordImmune™ (Cordyceps sinensis), the only Cordyceps on the market that tests for and declares its cordycepin content; and Corio-PSP™ (Coriolus versicolor), the mostresearched mushroom species for immune support. Remember to stop by our booth for a FREE coagulation health check ($85 value)!

BOOTH #313

CHANGEWELL TRAINING ACADEMY

900 RIDGEBURY ROAD RIDGEFIELD, CT 06877 P: 203-798-9988 us.boehringer-ingelheim.com

BOOTH #218

Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA welcome you to 12th Annual Cardiometabolic Health Congress and look forward to the opportunity to share the latest clinical information on our products. Visit http://us.boehringer-ingelheim.com or www.lilly.com. Follow us on twitter at @ boehringerus. Our Diabetes Alliance also welcomes you to visit

BOOTH #321 to Prizes

4400 HAZELBRIDGE WAY UNIT 680 RICHMOND, BC V6X3R8 CANADA P: 604-273-2233 www.canadarna.com We specialize in niche natural medicine for practitioners: Boluoke (lumbrokinase),

POBOX 7303 RANCHO SANTA FE, CA 92067 P: 858-775-0785 www.changewell.com ChangeWell Training Academy helps healthcare practitioners enhance their presence in person, on camera and online. Our consulting services help crystallize and memorialize your messaging so you can attract the types of patients you want to treat. In an era of increasing competition and growing social media awareness, healthcare practitioners must distinguish themselves from others who provide similar services. In our live and online programs, you learn to improve your presentation, persuasion, and promotion skills. We provide the ongoing Practice Enhancement Training program for the A4M; held twice a year in conjunction with their annual conferences.

IF YOU HAVE TYPE 2 DIABETES, YOU ARE AT 1 INCREASED RISK FOR HEART DISEASE

What’s the connection? People with diabetes are

2-4x MORE LIKELY

to develop cardiovascular disease, which includes heart attacks and strokes, than people without diabetes.2

Cardiovascular disease causes approximately

2/3

of deaths in people with type 2 diabetes, making it the #1 cause of death.2

Visit ForYourSweetHeart.com and sign up to receive more information about type 2 diabetes and heart disease. 1. American Heart Association. Cardiovascular Disease & Diabetes. (http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/ Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp/#.V_eeM3arRD9) Accessed: March 2017. 2. World Heart Federation. Cardiovascular Disease Risk Factors. (http://www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors/diabetes/). Accessed: September 2016. 3. National Diabetes Education Program. Snapshot of Diabetes. (http://www.nkfm.org/sites/default/files/documents/ndep_ diabetes_snapshot.pdf). Accessed: April 2017.

Participating Patient and Professional Organizations

PC--US-100319

08/17

www.CardiometabolicHealth.org

SUBMISSION TO PUBLICATION IN 3-5 WEEKS

… is a rapid, peer-reviewed medical journal published for physicians

… is a peer-topeer method of communicating the latest research to aid physicians when making treatment decisions

… is a platinum level partner of the Cardiometabolic Health Congress (CMHC)

… traces its roots back to 1916

… is distributed to hundreds of physicians within internal medicine and family practice across the US, in addition to its core subscriber base

Hundreds of US physicians within internal and family medicine receive Postgraduate Medicine. Reach this unique audience directly by submitting via our prioritized publication service: Fast Track gets your work published within 3-5 weeks while Rapid Track ensures publication in 5-7 weeks.

Why should you publish via Rapid or Fast Track in Postgraduate Medicine? • Planning ahead: Knowing the timelines allows you to plan publication to coincide with anything from a thesis defence to a drug regulatory approval • Increased visibility: The sooner your paper is published, the sooner it can be read and cited • Expert advice: Our experienced editors are on hand to assist with pre-submission advice, peer review guidance, and provide tips on how to maximise the impact of your article • Unparalleled service: Our Fast Track service is the fastest way to publish, quicker than any competitor • Recognised stamp of quality: Postgraduate Medicine is a MEDLINE-indexed journal with a rigorous and independent peer review process. It has an Impact Factor of 2.062* *(© 2016 Clarivate Analytics, Journal Citation Reports®)

Visit tandfonline.com/ipgm to learn more about publishing Rapid Track or Fast Track in Postgraduate Medicine

EXHIBITOR LISTINGS CINSULIN

BOOTH #213

to Prizes

21111 VICTOR STREET UNIT. 1 TORRANCE, CA 90503 P: 404-983-2074 www.cinsulin.com CinSulin® water extract of cinnamon is a patented ingredient that uses a 100% water extraction process to separate and largely remove the unwanted fat-soluble compounds that naturally occur in the cinnamon plant. The beneficial watersoluble compounds are then concentrated into a 10:1 ratio, creating a potent cinnamon extract. The 5 human clinical studies and meta-analysis on CinSulin® show the positive impact that water extracted cinnamon has on blood sugar levels.

CLEVELAND HEARTLAB

BOOTH #208

to Prizes

6701 CARNEGIE AVENUE, STE 500 CLEVELAND, OH P: 216-213-3656 www.clevelandheartlab.com Cleveland HeartLab offers innovative, scientifically proven, and medically relevant biomarkers that are predictive of cardiovascular risk. We offer inflammatory and other advanced biomarker testing that practitioners from across North America, Europe and Asia use in the management and prevention of heart disease. Our novel biomarker technologies are offered through our CAP-accredited and CLIAcertified clinical reference laboratory. We also run a research and development laboratory where next-generation cardiovascular disease biomarkers are

being developed for use through our clinical laboratory. This valuable pipeline of tests is part of an exclusive intellectual property portfolio that targets large, under-addressed markets. Additionally, Cleveland Heartlab is ISO 13485 certified and the exclusive providers of Universal CardioMPO? kits.

CORCEPT THERAPEUTICS

BOOTH #419

to Prizes

149 COMMONWEALTH DRIVE MENLO PARK, CA 94025 P: 650-688-3270 www.corcept.com Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym® (mifepristone) 300mg Tablets, a first generation GR antagonist, for the control of hyperglycemia associated with persistent Cushing syndrome is the company’s first FDA-approved medication. www.corcept.com

DIEM LABS

BOOTH #215 321 MAIN STREET SUITE 100 BUFFALO, WY 82834 P: 504-813-4656 www.adiposano.com DIEM Labs seeks to provide novel solutions to unmet needs in the marketplace providing better access for both patients and physicians. Our expertise is a focus upon metabolic health with more than one hundred years of experience among the senior management team. We look forward to meeting you and sharing an introduction to our new products

GENOVA DIAGNOSTICS

BOOTH #209 63 ZILLICOA ST ASHEVILLE, NC 28801 P: 800-522-4762 www.gdx.net Genova Diagnostics is a leading clinical laboratory applying systems-based testing approaches to the diagnosis, treatment and prevention of complex chronic disease. Genova specializes in clinical laboratory services with actionable information.

www.CardiometabolicHealth.org

Proud Media Partner of the Cardiometabolic Health Congress

Live meeting coverage! Cardiology Today is reporting live from CMHC. Get up-to-the-minute news and perspective straight from the podium on Healio.com, the online home of Cardiology Today. In print and online, you’ll get the latest meeting coverage along with expert perspective from our renowned Editorial Board and other leading clinicians. Women’s Heart Notes 18

Drug Risk Update 38

2 decades of structural heart disease 40

Healio.com/Cardiology

A N Ni

Ver

Volume 20 • Number 9 September 2017

SArY

Cardiology covered.

Carl J. pepine, mD, Chief Medical Editor

cover Story

Source: UPMC; reprinted with permission..

Sickle cell disease and the heart: Awareness increases in cardiology community

mark t. Gladwin, mD, from the University of pittsburgh School of medicine, said patients with sickle cell disease are living longer, but are prone to CV complications as they age.

Sickle cell disease once carried a life span that ended in the teenage years. As more research is conducted and new treatments become available, patients with sickle cell disease are now living longer — on average, between 40 and 60 years. However, patients with sickle cell disease who are now living longer appear to have elevated risk for CV conditions. “What’s happening is our patients with sickle cell are living and are developing chronic damage to their blood vessels and heart.” Mark T. Gladwin, MD, Jack D. Meyers Professor and Chair, chairman of the department of medicine, and director of the Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute at University of Pittsburgh Medical Center and University of Pittsburgh School of Medicine, told Cardiology Today. According to the American Society of Hematology and the NIH, between 70,000 and 100,000 Americans and 8% of black individuals in the United States have sickle cell disease. Most physicians are aware of the CV damage that may occur in patients with sickle cell disease through different CV conditions, but the challenge Cover Story continues on page 10

Prevention

Stroke All Stroke articles start on page 17

Statins after ischemic stroke beneficial but underutilized Discontinuing statin therapy after ischemic stroke increased risk for recurrent stroke, but more than half of U.S. stroke survivors were not prescribed statins on discharge, according to two studies published in the Journal of the American Heart Association. In one study, cessation of statin therapy within 3 to 6 months following a first ischemic stroke was associated with a 42% higher risk for recurrent stroke within 1 year.

Statins continues on page 17

Participants who ate a healthier plant-based diet had a decreased risk for CHD, according to a study published in the Journal of the American College of Cardiology. “When we examined the associations of the three food categories with heart disease risk, we found that healthy plant foods were associated with lower risk, whereas less healthy plant foods and animal foods were associated with higher risk,” Ambika Satija, ScD, a postdoctoral fellow at the Harvard T.H. Chan School of Public Health, said in a press release. “It’s apparent that there is a wide variation in the nutritional quality of plant foods, making it crucial to take into consideration the quality of foods in a plant-based diet.” Researchers reviewed data from 73,710 women from the Nurses’ Health Study, 92,329 women from the Nurses’ Health Study II and 43,259 men from the Health

Meeting coverage

trial ScorecardS All Surgery articles start on page 23

licorn Preoperative Levosimendan in CABG Patients With Poor LV Function Design:

randomized, parallel-assignment, double-blind

patients: Centers: Country:

335 13 France reSULtS: See page 12

All prevention articles start on page 5

Adherence to a healthy plant-based diet may decrease CHD risk

Daily news

Physician perspective

HF and tranSPlantation All HF and transplantation articles start on page 22

Professionals Follow-Up Study who did not have chronic diseases at baseline. Participants completed a semiquantitative food frequency questionnaire every 2 to 4 years. Three kinds of a plant-based diet were developed based on questionnaire responses: plant-based diet index, healthful plant-based diet index and unhealthful plant-based diet index. The overall plant-based diet index included mainly plant-based foods with no animalbased foods, including dairy, fish and meat. The healthful plant-based diet included everything from the overall plant-based diet without less healthy foods such as refined grains, potatoes, sugar-sweetened beverages and fruit juices. The unhealthful plant-based diet featured less healthful plant-based foods known to be associated with elevated risk for certain diseases.

Weight gain may affect heart structure, increase risk for HF Weight gain was associated with pathologic cardiac remodeling and an increased long-term risk for HF, according to new data from the Dallas Heart Study published in the Journal of the American Heart Association. “Any weight gain may lead to abnormal changes in the heart above and beyond one’s baseline weight,” Ian J. Neeland, MD, a cardiologist, assistant professor of medicine and Dedman Family Scholar in Clinical Care at University of Texas Weight gain continues on page 22

Plant-based diet continues on page 9

FDA NewS

prACtiCe mANAGemeNt

iN tHe JoUrNALS

Biotronik announces approval of ICD systems for HF

Readmission decline may be linked to lower mortality in acute MI, HF, pneumonia

Technology may reverse cell aging process, reduce early CVD risk

pAge 16

pAge 33

pAge 42

CME Video

A SLACK Incorporated® publication

Healio.com/Cardiology 20

www.CardiometabolicHealth.org

17-1274

EXHIBITOR LISTINGS GREAT PLAINS LABORATORY

G.S INNOVATIONS

IDEAL PROTEIN OF AMERICA

BOOTH #319

BOOTH #424

BOOTH #314

11813 WEST 77TH STREET LENEXA, KS 66214 P: 913-341-8949 www.greatplainslaboratory.com

7182 GALLEY DR. LAS VEGAS, NV 89147 P: 844-556-3120 www.gsinnovaitonsinc.com

3135 SR 580 SUITE 5 SAFETY HARBOR, FL 34695 P: 866-314-4447 www.idealprotein.com

The Great Plains Laboratory, Inc. (GPL) is the leader in metabolic testing for patients with neurological, behavioral, gastrointestinal, and immunological disorders. Our Organic Acids Test is the most comprehensive available on the market with over 70 markers, including those for yeast, bacteria, oxalates, neurotransmitters, vitamin deficiencies, oxidative stress, fatty acids and more. Our toxic, non-metal chemical profile, GPL-TOX, screens for the presence of over 170 different toxic chemicals by testing 18 unique metabolites, including organophosphate pesticides, phthalates, benzene, xylene, vinyl chloride, and pyrethrin insecticides, and also includes a marker for mitochondrial damage. In October 2015, we launched a urine test for glyphosate, the worldâ&#x20AC;&#x2122;s most widely used toxic herbicide. Our newest test, GPL-SNP1000, is a genetic profile that tests over 140 genes and over 1,000 SNPs in nine critical pathways for health. We look forward to par tnering with you to provide your patients with the most comprehensive testing and most personalized treatment plans possible.

G.S. Innovations provides a variety of healthcare solutions to many different industries. We work on developing and identifying the best medical care to help diverse professional groups overcome their challenges.

The Ideal Protein Weight Loss Protocol is medically designed and developed and is consistent with evidence-based guidelines, to help obese and overweight patients or clients achieve safe, long-term weight loss and maintain it. The Protocol helps to reverse the imbalance in insulin that occurs with the typical Western diet and that contributes to weight gain and metabolic syndrome. Physicians report that after successful completion of the Ideal Protein Weight Loss Protocol, patients experience significant improvement in metabolic parameters. Individualized, professional health coaching helps patients or clients learn proper nutrition and new eating habits.

HUMAN METABOLOME TECHNOLOGIES

BOOTH #320 24 DENBY RD. STE 217 BOSTON, MA 02134 P: 617-987-0554 www.humanmetabolome.com Human Metabolome Technologies is a contract research based metabolomics profiling company. We use state of the art mass spec based techniques to accurately detect and quantitate small molecule compounds frequently associated with bioenergetics, secondary and tertiary metabolic pathways, and biomarker candidates. Our platforms and methods are suitable for a wide range of samples from pre-clinical to clinical.

www.CardiometabolicHealth.org

EXHIBITOR LISTINGS JANSSEN PHARAMCEUTICALS, INC.

BOOTH #518 1125 TRENTON-HARBOURTON RD. TITUSVILLE, NJ 08560 P: 800-526-7736 www.janssen.com/us/ Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, aims to create a world without disease. Transforming lives by finding new and improved ways to prevent, intercept, treat and cure disease inspires us. Driven by our commitment to patients, we bring together the best minds and pursue the most promising science in areas of critical need - mental health, cardiovascular disease and diabetes, among others. We are Janssen. We collaborate with the world for the health of everyone in it

KASTLE THERAPEUTICS

BOOTH #326 181 W. MADISON ST. SUITE 3400 CHICAGO, IL 60602 P: 312-883-5700 www.kastletherapeutics.com Our Mission is to serve patients who have significant unmet medical needs and are underserved. To solve challenges for therapeutic developers and manufacturers. To support quality of care for patients with severe diseases.

KYOUI

BOOTH #324 6787 W TROPICANA AVE #274 LAS VEGAS, NV 89103 P: 855-465-9684 www.kyoui.com Kyoui is a manufacturer of a unique patented device created to fight and prevent periodontal disease that affects 75% of Americans leading to several systemic diseases such as stroke, cardiovascular disease, diabetes, etc. When we know that 91% of patients with heart disease also have periodontal disease, we need to do something to stop this silent killer called periodontitis. Our mission is to raise awareness about oral-systemic health link and our goal is to help people prevent and fight periodontal disease for a better overall health.

www.CardiometabolicHealth.org

KOWA PHARMACEUTICALS AMERICA, INC.

BOOTH #305

to Prizes

530 INDUSTRIAL PARK BLVD MONTGOMERY, AL 36064 P: 334-288-1288 www.kowapharma.com A legacy of trust. A future of care. Established in 2008, Kowa Pharmaceuticals, Inc., is committed to developing and delivering safe, effective solutions in the field of cardiometabolic therapeutics. We do this by maintaining high ethical and professional standards--and it all starts with people. By empowering our employees to live this mission, we can create a healthier vision for the future.

MERCK & CO., INC.

BOOTH #413 2000 GALLOPING HILL ROAD KENILWORTH, NJ 07033 P: 908-740-4000 www.merck.com For over a century, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships.

www.CardiometabolicHealth.org

EXHIBITOR LISTINGS METAGENICS INC.

BOOTH #418 25 ENTERPRISE STE 200 ALISO VIEJO, CA 92656 P: 800-692-9400 www.metagenics.com Metagenics was founded on a revolutionary idea our genes do not pre-determine our health potential, and through nutrition, we can impact how our genes express themselves. With the vision to make nutritional intervention a first line therapy in the prevention and management of disease, we’ve employed the latest research and technologies to deliver a wide range of nutraceuticals and medical foods for targeted nutritional support. Our products are clinically tested and backed by science. And because we only offer our products and programs through healthcare practitioners, Metagenics has become one of the most trusted health and wellness brands worldwide.

NOVARTIS PHARMACEUTICALS CORPORATION

BOOTH #520 ONE HEALTH PLAZA EAST HANOVER, NJ 07936 P: 862-778-0000 www.pharma.us.novartis.com Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas.

NOVO NORDISK, INC

BOOTH #204 376 BOSTON POST ROAD AMHERST, NH 03031 P: 603-715-7256 www.novonordisk.com Novo Nordisk- U.S. Novo Nordisk, Inc., is the US affiliate of Novo Nordisk A/S. We are one of the world’s leading diabetes care companies. The company’s US headquarters is located in Plainsboro, NJ. Clayton, NC Diabetes Finished Products helps support Novo Nordisk as a leader in diabetes by providing a complete product portfolio of insulin and GLP-1 products. Diabetes Active Pharmaceutical Ingredients will support Novo Nordisk in production and engineering. Seattle, WA Established in 2009, the Novo Nordisk Research Center is focused on early discovery projects

www.CardiometabolicHealth.org

within the diabetes and obesity areas. West Lebanon, NH Located in West Lebanon, New Hampshire, Novo Nordisk US Bio Production, Inc. is a biopharmaceutical manufacturing facility that works to produce trusted products for people living with the rare bleeding disorder known as hemophilia. Indianapolis, IN NNRCI (Novo Nordisk Research Center Indianapolis, Inc) is focused on early discovery projects within the diabetes and obesity areas.

REGENERON-SANOFI

BOOTH #521 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 P: 347-213-7160 www.Regeneron.com Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents lifetransforming medicines for people with serious diseases. Founded and led by physician-scientists for nearly 30 years, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and over a dozen product candidates, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, and infectious and rare diseases. Regeneron is accelerating and improving the traditional drug development process through its unique VelociSuite® technologies, including VelocImmune® which yields optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.

GET YOUR HoFH PATIENTS

CLOSER TO GOAL

ADDING KYNAMRO® (mipomersen sodium) INJECTION TO CURRENT TREATMENT REGIMENS HELPED ADULT PATIENTS REDUCE THEIR LDL-C BY AN ADDITIONAL 113 mg/dL1,2* } KYNAMRO lowers LDL-C by limiting production of VLDL and downstream atherogenic particles1-3 } KYNAMRO delivers maximal LDL-C results within 6 months,1 with sustained reductions (-28% mean change) as long as 2 years3 VLDL=very-low density lipoprotein

*Based on data from a randomized, double-blind, placebo-controlled, 26-week trial in 51 subjects with HoFH (34 KYNAMRO, 17 placebo), KYNAMRO 200 mg/mL significantly reduced LDL-C and improved all other measured atherogenic lipoproteins when used as an adjunct to lipid-lowering medications and diet.

INDICATIONS AND USAGE KYNAMRO is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

LIMITATIONS OF USE • The safety and effectiveness of KYNAMRO have not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia (HeFH) • The effect of KYNAMRO on cardiovascular morbidity and mortality has not been determined • The safety and effectiveness of KYNAMRO as an adjunct to LDL apheresis have not been established; therefore, the use of KYNAMRO as an adjunct to LDL apheresis is not recommended

Please see additional Brief Summary of Prescribing Information on adjacent page. References: 1. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, 2010;375(9719):998-1006. 2. KYNAMRO [prescribing information]. Chicago, IL; Kastle Therapeutics; 2016. 3. Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J. 2015;36(9):566–575.

KYNAMRO® (mipomersen sodium) INJECTION, FOR SUBCUTANEOUS USE BRIEF SUMMARY OF PRESCRIBING INFORMATION WARNING: RISK OF HEPATOTOXICITY See full prescribing information for complete boxed warning. KYNAMRO can cause elevations in transaminases. In the KYNAMRO clinical trial in patients with HoFH, 4 (12%) of the 34 patients treated with KYNAMRO compared with 0% of the 17 patients treated with placebo had at least one elevation in alanine aminotransferase (ALT) ≥3x upper limit of normal (ULN). There were no concomitant clinically meaningful elevations of total bilirubin, international normalized ratio (INR) or partial thromboplastin time (PTT).

vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms), increases in bilirubin ≥2x ULN, or active liver disease, discontinue treatment with KYNAMRO and identify the probable cause. Alcohol may increase levels of hepatic fat and induce or exacerbate liver injury. It is recommended that patients taking KYNAMRO should consume no more than one alcoholic drink per day. Caution should be exercised when KYNAMRO is used with other medications known to have potential for hepatotoxicity, for example isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. The effect of concomitant administration of KYNAMRO with other hepatotoxic medications is unknown. More frequent monitoring of liver-related tests may be warranted. KYNAMRO has not been studied concomitantly with other LDL-lowering agents that can also increase hepatic fat. Therefore, the combined use of such agents is not recommended.

KYNAMRO also increases hepatic fat, with or without concomitant increases in transaminases. In the trials in patients with heterozygous familial hypercholesterolemia (HeFH) and hyperlipidemia, the median absolute increase in hepatic fat was 10% after 26 weeks of treatment, from 0% at baseline, measured by magnetic resonance imaging (MRI). Hepatic steatosis is a risk factor for advanced liver disease; including steatohepatitis and cirrhosis.

5.2

Measure ALT, AST, alkaline phosphatase, and total bilirubin before initiating treatment and then ALT, AST regularly as recommended. During treatment, withhold the dose of KYNAMRO if the ALT or AST are ≥3x ULN. Discontinue KYNAMRO for clinically significant liver toxicity.

5.3

Because of the risk of hepatotoxicity, KYNAMRO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the KYNAMRO REMS. Prescribe KYNAMRO only to patients with a clinical or laboratory diagnosis consistent with HoFH. The safety and effectiveness of KYNAMRO have not been established in patients with hypercholesterolemia who do not have HoFH. 1 INDICATIONS AND USAGE KYNAMRO® (mipomersen sodium) injection is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). Limitations of Use • The safety and effectiveness of KYNAMRO have not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia (HeFH) • The effect of KYNAMRO on cardiovascular morbidity and mortality has not been determined • The safety and effectiveness of KYNAMRO as an adjunct to LDL apheresis have not been established; therefore, the use of KYNAMRO as an adjunct to LDL apheresis is not recommended 2.1

GENERAL DOSING INFORMATION

Before beginning treatment with KYNAMRO, measure transaminase (ALT, AST), alkaline phosphatase, and total bilirubin. The recommended dose of KYNAMRO is 200 mg once weekly as a subcutaneous injection. 4

CONTRAINDICATIONS

KYNAMRO REMS

Because of the risk of hepatotoxicity, KYNAMRO is available only through a limited program under the REMS. Under the KYNAMRO REMS, only certified health care providers and pharmacies may prescribe and distribute KYNAMRO. Further information is available at www.KynamroREMS.com or by telephone at 1-877-KYNAMRO (1-877-596-2676). INJECTION SITE REACTIONS

Injection site reactions have been reported in 84% of patients receiving KYNAMRO therapy. These local reactions typically consist of one or more of the following: erythema, pain, tenderness, pruritus and local swelling. To minimize the potential for injection site reactions, proper technique for subcutaneous administration should be followed. Injection site reactions do not occur with all injections but resulted in discontinuation of therapy in 5% of patients in pooled Phase 3 trials. 5.4

FLU-LIKE SYMPTOMS

Flu-like symptoms have been reported in 30% of patients receiving KYNAMRO therapy and include one or more of the following: influenza-like illness, pyrexia, chills, myalgia, arthralgia, malaise or fatigue. Flu-like symptoms, which typically occur within 2 days after an injection, do not occur with all injections but resulted in discontinuation of therapy in 3% of patients in pooled Phase 3 trials. 6

ADVERSE REACTIONS

In clinical trials the most commonly-reported adverse reactions were injection site reactions (84%), flu-like symptoms (30%), nausea (14%), headache (12%), and elevations in serum transaminases, specifically ALT (10%). 7

DRUG INTERACTIONS

No clinically relevant pharmacokinetic interactions reported between KYNAMRO and warfarin, or between KYNAMRO and simvastatin or ezetimibe. 8

USE IN SPECIFIC POPULATIONS

8.1

Pregnancy Category B

There are no adequate and well-controlled studies in pregnant women. KYNAMRO should be used during pregnancy only if clearly needed. 8.3

Nursing Mothers

It is not known whether KYNAMRO is excreted in human milk. Because many drugs are excreted in human milk a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

KYNAMRO is contraindicated in the following conditions:

8.4

• Moderate or severe hepatic impairment (Child-Pugh B or C) or active liver disease, including unexplained persistent elevations of serum transaminases.

Safety and effectiveness have not been established in pediatric patients.

• Patients with a known hypersensitivity to any component of this product.

8.6

KYNAMRO may cause fetal harm. Females who become pregnant during KYNAMRO therapy should notify their healthcare provider. Females of reproductive potential should use effective contraception during KYNAMRO therapy.

WARNINGS AND PRECAUTIONS

5.1

RISK OF HEPATOTOXICITY

KYNAMRO can cause elevations in transaminases and hepatic steatosis. Prior to initiation of treatment with KYNAMRO, measure a full liver panel to include ALT, AST, total bilirubin, and alkaline phosphatase. If the baseline liver-related tests are abnormal, consider initiating KYNAMRO after an appropriate work-up and the baseline abnormalities are explained or resolved. During the first year, conduct liver-related tests monthly (ALT and AST, at a minimum). After the first year, conduct these tests at least every 3 months. Discontinue KYNAMRO for persistent or clinically significant elevations. If transaminase elevations are accompanied by clinical symptoms of liver injury (e.g., nausea,

8.7

Pediatric Use Females of Reproductive Potential

Renal Impairment

The safety and efficacy of KYNAMRO treatment in patients with known renal impairment or in patients undergoing renal dialysis have not been established. Due to the lack of clinical data and KYNAMRO’s renal safety profile, KYNAMRO is not recommended in patients with severe renal impairment, clinically significant proteinuria, or on renal dialysis. 17

PATIENT COUNSELING INFORMATION

See the KYNAMRO Full Prescribing Information for the Patient Counseling Information. Please see full Prescribing Information, including Boxed Warning,

at KYNAMRO.com.

EXHIBITOR LISTINGS RELYPSA

SPECTRACELL LABORATORIES

THE CORE GROUP

BOOTH #525

BOOTH #304

BOOTH #412

100 CARDINAL WAY REDWOOD CITY, CA 94063 P: 650-421-9500 www.relypsa.com

10401 TOWN PARK DR. HOUSTON, TX 77072 P: 800-227-5227 www.spectracell.com

40 HAMPSHIRE ROAD Mahwah, NJ 07430 P: 800-573-2031 www.vanguardpharma.com

Relypsa is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening. We are focused on developing medicines that will change treatment paradigms. Our mission is to improve patients? lives through the discovery, development and delivery of therapeutics that leverage polymer science and other novel approaches.

SpectraCell Laboratories, Inc. is a leading clinical laboratory specializing in personalized disease prevention and management solutions. Our pioneering nutritional and cardiometabolic testing, driven by state-of-the-art technology, assesses a spectrum of risk factors and biomarkers for optimum wellness. Through our dedication to research and development, SpectraCell also provides innovative solutions for hormone health and genetics.

Who is The Core Group, you ask? Well, our name is what we do. CORE stands for Clinical Outcomes + Revenue Enhancement. Our sole purpose is to bring you, members of the medical community, products and services that serve a valuable purpose in your practice, helping you optimally manage your patients and get to positive clinical outcomes as fast and as efficiently as possible. But, “positive clinical outcomes” is only half of the story – we ALSO want to bring you products and services that add incremental revenue to your practice! We understand the financial pressures that you are under these days. It doesn’t serve your practice or your patients well if your office is not thriving financially, so we want to help! That is our mission: Clinical Outcomes + Revenue Enhancement.

to Prizes

TENSTIM SECA

BOOTH #318 13601 BENSON CHINO, CA P: 800-542-7322 www.mbca.seca.com seca, the worldwide market leader in medical measuring systems and scales presents the first body composition analyzers designed for medical use and validated to the Four Compartment Model – the gold standard for fat mass calculation. Offering a non-invasive analysis that measures fat and fat-free mass, visceral adipose tissue, skeletal muscle mass, intra and extra-cellular water, all at a clinical level of precision. Monitor vital parameters and assist patients with understanding the key risk factors and indicators that contribute to obesity, metabolic syndrome, diabetes and chronic disease.

BOOTH #225 582 TAM O SHANTER DR LAS VEGAS, NV 89118 P: 401-829-1434 WWW.TENSTIM.COM At tenstim international inc, our goal is to provide you with courteous, expedient, professional service of the highest caliber. The customer always comes first. Our staff offers quality and reliable services you can count on. Tens stands for trans-cutaneous (through the skin) electrical nerve stimulation and is a treatment that uses electrical currents to relieve pain and provides other therapeutic benefits. A gentle electrical current is passed through electrodes which are attached to the skin near the site of the pain or discomfort. The pulses send bio-electrical signals through the central nervous system, thus blocking pain receptors. The same way a strong painkiller would work.

to Prizes

UNISOURCE HEALTH

BOOTH #205

to Prizes

1894 EAST WILLIAMS ST. SUITE 307 CARSON CITY, NV 89701 P: 775-883-6465 WWW.UNISOURCEHEALTH.COM UniSource Health offers the RM-3A Medical Device. It is a five time FDA cleared device which provides an innovative unique fast analytical screening system for risk factors pertaining to diabetes, cardiovascular disease, neuropathy and ANS dysfunction as well as other wellness and longevity markers. The non-invasive RM-3A and ABI devices are designed for in-practice early detection of risk variables offering up-to-the-minute data essential to whole-person analysis.

www.CardiometabolicHealth.org

PROFESSIONAL NON-CME MEDICAL EDUCATION Round out your CMHC educational experience by attending Professional Medical Education/Product Theater symposia focused on novel therapies. These non-certified activities are planned solely by the sponsoring organizations/companies.

SYMPOSIUM

WEDNESDAY, OCTOBER 4 11:00AM – 12:00PM

THE CARDIOMETABOLIC IMPLICATIONS OF OBESITY AND NUTRITIONAL STRATEGIES FOR PREVENTION Faculty: Frank B. Hu, MD, PhD

The prevalence of obesity in the US has reached epidemic proportions. Obesity is defined as having a body mass index (BMI) greater than 30; rates for it have more than doubled in adults and children since 1970. Recent figures indicate over 78 million US adults are obese today. Obesity is associated with numerous health issues including arthritis, cancer and cardiovascular disease (CVD). Obesity is linked to multiple comorbid conditions underlying CVD including hypertension, diabetes, and dyslipidemia and is often due to consequences of heart-damaging lifestyle choices including lack of exercise and poor dietary choices. Diet is critical to development and prevention of heart disease and is a key modifiable risk factor. In this presentation, Dr.

www.CardiometabolicHealth.org

Hu will review various studies highlighting implications of obesity on conditions associated with –and contributing to— CVD. He will discuss research on dietary changes to reduce cardiometabolic risk and improve outcomes in this patient population. Sponsored by Metagenics Institute

LUNCH SYMPOSIUM

WEDNESDAY, OCTOBER 4 12:00PM – 1:15PM

REPATHA® (EVOLOCUMAB): TAKE THE NEXT STEP Faculty: Yehuda Handelsman, MD

This program provides an overview of Repatha®, including dosing and administration. A discussion of appropriate patients will be supplemented by relevant hypothetical examples. Sponsored by Amgen Inc.

PROFESSIONAL MEDICAL EDUCATION SYMPOSIUM (LIGHT BITES)

DINNER SYMPOSIUM

WEDNESDAY, OCTOBER 4 5:00PM – 6:00PM

THURSDAY, OCTOBER 5 6:00PM – 7:00PM

AWAKEN A TRANSFORMATION IN TYPE 2 DIABETES MANAGEMENT Faculty: Yehuda Handelsman, MD

Sponsored by Janssen Pharmaceuticals, Inc.

SYMPOSIUM (LIGHT BITES)

WEDNESDAY, OCTOBER 4 6:00PM – 7:00PM

ADVANCEMENTS IN THE MANAGEMENT OF PATIENTS WITH TYPE 2 DIABETES: RESULTS FROM A LARGE CARDIOVASCULAR OUTCOMES TRIAL

CLINICAL EVALUATION OF PURE EPA Faculty: Matthew J. Budoff, MD

Hear an expert medical presentation entitled Clinical Evaluation of Pure EPA, which provides a brief overview of TGs and research on other lipids, lipoproteins and inflammatory parameters related to CV disease, despite statin-controlled LDL-C. The clinical program for pure EPA VASCEPA® (icosapent ethyl), including the ongoing CV outcome trial REDUCE-IT™, will be reviewed. In the treatment of patients with elevated TGs, the clinical difference between and effects of EPA and DHA omega-3s and the issues concerning patient use of fish oil supplements will be discussed.

Faculty: Michael H. Davidson, MD

Sponsored by Akcea Therapeutics

www.CardiometabolicHealth.org

ASSOCIATION & MEDIA PARTNERS

The 2017 Cardiometabolic Health Congress gratefully acknowledges the following level sponsors:

ELITE

PLATINUM MEDIA PARTNER BRONZE

ASSOCIATION PARTNERS American Board of Clinical Lipidology American Medical Womenâ&#x20AC;&#x2122;s Association American Society of Endocrine Physician Assistants Asian Pacific Society of Cardiology Congress Association of Black Cardiologists, Inc. Clinical & Experimental Cardiology Massachusetts Coordinating Body of AADE Obesity Medicine Association Obesity Society Society for the Study of Ingestive Behavior World Obesity

MEDIA PARTNERS Cardio Renal Medicine Close Concerns Mary Ann Liebert, Inc. Publishers Medical Sciences Nutrition Today PharmaVoice Postgraduate Medicine

www.CardiometabolicHealth.org

PME (PROFESSIONAL MEDICAL EDUCATION)

CMHC Education Resource Center

EARN CME/CE CREDITS

CMHC Online offers a single access point for educational resources and online courses featuring the expert content and faculty from CMHC live events. Stay current on the latest clinical research and strategies, while testing your knowledge of essential topics in cardiometabolic risk management and CVD prevention. Select from a comprehensive array of complimentary CME-CE activities in a variety of formats to meet your needs, available on-demand and on-the-go!

C H O O S E YO U R F O RMAT

Sta rt Lea rn i n g To day !

www. c ard i o m e t a b o l i c h ea l t h . o rg / o n l i n e c m e . h t ml

ACCESS THIS YEAR’S PRESENTATIONS, ANYTIME, ANYWHERE! Order onsite and save over $900! SALES BOOTH: Registration Foyer Online access to all presentations from any computer or mobile device Download PDF’s and MP3 files for mobile access CME Available right from your OnDemand Player

CME/CE SYMPOSIA WEDNESDAY, OCTOBER 4

FRIDAY, OCTOBER 6

BUSINESS OF MEDICINE CME SYMPOSIUM

CME BREAKFAST SYMPOSIUM A

1:20 PM– 2:20 PM

Constitution Ballroom

BEST PRACTICES: EFFICIENT AND COSTEFFECTIVE MANAGEMENT OF THE AUTHORIZATION PROCESS

Faculty: Pamela B. Morris, MD; Kim K. Birtcher, PharmD Supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals.

6:45 AM – 7:45 AM

Constitution Ballroom

INTERVENTIONAL CARDIOLOGY DELIVERED WITH A FORK Faculty: Stephen Devries, MD Supported by educational funding from Tarsus Cardio Inc. dba Cardiometabolic Health Congress. CME BREAKFAST SYMPOSIUM B

THURSDAY, OCTOBER 5 CME BREAKFAST SYMPOSIUM

6:40 AM – 7:55 AM

Grand Ballroom

CLOSING THE GAP CREATED BY CLINICAL INERTIA: NEW STRATEGIES FOR T2DM TREATMENT

Faculty: Robert H. Eckel, MD (Chair); Yehuda Handelsman, MD; Athena Philis-Tsimikas, MD; Julio Rosenstock, MD Supported by an educational grant from Sanofi US. CME LUNCH SYMPOSIUM

12:15 PM – 1:15 PM

Grand Ballroom

NAVIGATING UPDATED GUIDELINES AND NEW THERAPIES FOR THE DIAGNOSIS AND TREATMENT OF HEART FAILURE Faculty: Keith C. Ferdinand, MD (Chair); Clyde W. Yancy, MD; JoAnn Lindenfeld, MD Supported in part by an educational grant from Novartis Pharmaceuticals Corporation.

Grand Ballroom

ENSURING ACCESS TO EVIDENCE-BASED THERAPIES IN HIGH RISK SPECIAL POPULATIONS: STATIN INTOLERANCE, RACIAL/ETHNIC MINORITIES AND FAMILIAL HYPERCHOLESTEROLEMIA Faculty: Keith C. Ferdinand, MD; Catherine Davis Ahmed, MBA Supported by educational grants from the Association of Black Cardiologists, Inc. and Tarsus Cardio Inc. dba Cardiometabolic Health Congress. CME LUNCH SYMPOSIUM

12:25 PM – 1:40 PM

Grand Ballroom

CV PROTECTION: IS IT ACHIEVABLE IN PATIENTS WITH T2DM?

Faculty: Jay S. Skyler, MD (Chair); Wendy S. Lane, MD; Robert H. Eckel, MD; Benjamin M. Scirica, MD Multi-supported by educational grants from Novo Nordisk, Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

SATURDAY, OCTOBER 7 CME BREAKFAST SYMPOSIUM

CME DINNER SYMPOSIUM

7:00 PM – 8:00 PM

6:45 AM – 7:45 AM

Grand Ballroom

ADVANCES IN INSULIN THERAPY: ADDRESSING PROVIDER AND PATIENT SAFETY CONCERNS Faculty: Anne L. Peters, MD Supported in part by an educational grant from Novo Nordisk.

6:45 AM – 7:45 AM

Constitution Ballroom

HYPERKALEMIA MANAGEMENT AND MONITORING IN HIGH-RISK PATIENTS: IMPROVING HEART FAILURE MANAGEMENT AND OUTCOMES Faculty: George L. Bakris, MD (Chair); JoAnn Lindenfeld, MD Supported in part by an educational grant from Relypsa, Inc.

www.CardiometabolicHealth.org

to Prizes

THURSDAY , OCTOBER 5

DRAWING WILL TAKE PLACE AT

5:15PM How the Game Works As an attendee, you will receive a passport book with your registration materials onsite at the conference. To play:

CHANCES TO WIN!

FRIDAY, OCTOBER 6 3rd Prize

DRAWING WILL TAKE PLACE AT

6:15PM

2nd Prize

1. Visit each booth listed on the passport. 2. Speak and engage with the exhibitor; take some time to view and learn from their demonstrations. 3. Receive a sticker from the exhibitor to add to their corresponding square on your passport. 4. Once you have filled ALL the squares on your passport, return your completed game card to the CMHC exhibit booth (#20) and you will be qualified to participate in the Grand Prize Drawing. The Grand Prize Drawing will be awarded during the Boston Block Party Reception on Friday, October 6th. Attendees must be present in the Exhibit Hall to qualify for the prize drawings.

Prize Drawings

CMHC Exhibit Hall Passport to Prizes! The Grand Prize Drawing will be awarded during the Boston Block Party Reception on Friday, October 6th. Attendees must be present in the Exhibit Hall to qualify for the prize drawings. www.cardiometabolichealth.org

The Grand Prize Drawing will take place Friday, October 6th during the Boston Block Party Reception in the Exhibit Hall. Only participants who complete the game card with all sponsor stickers and participant contact information will be eligible for the prize drawings. Winners will be drawn at random and must be present at the prize drawing to win. To claim prizes, winners must show identification. Only one prize per participating attendee.

SCIENTIFIC EXHIBIT HALL 001. Evaluation of endothelial function in patients with Type2 Diabetes Mellitus attending a tertiary care medical centre in South India

Friday, October 6, 2017 9:45 – 10:45AM, 3:00-4:00PM

U Pingali, S Yashmaina, MUR Naidu Nizam’s Institute of Medical Sciences (NIMS). Hyderabad, India 002. A Study of highly standardized aqueous extract of Terminalia chebula 250mg, 500mg versus Placebo in modifying cardiovascular risk with special reference to Endothelial dysfunction in patients with Type2 Diabetes Mellitus

Friday, October 6, 2017 9:45 – 10:45AM, 3:00-4:00PM

U Pingali, C Nutalapati, N Koilagundla Nizam’s Institute of Medical Sciences (NIMS). Hyderabad, India 003. Self-Image, Obesity, and African American Women

M Epstein1, M Mayo2, D Garza2, D Wilson2, G Bakris3 1 Univ of Miami, Leonard M. Miller Sch of Med, Miami, FL. 2Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA. 3Univ of Chicago Med, Chicago, IL. 006. The Australian perspective on premature coronary artery disease: prevalence and risk factors

Thursday, October 5, 2017 10:20-11:20 AM, 2:30-3:30PM

R Gilhotra1, R Gunnarsson1,2, S Sutcliffe1,2 1 James Cook University, Australia. 2Cairns Hospital, Cairns, Australia. 007. Wide Pulse Pressure Associated with Low Bone Mineral Density among Adult USA Population: Analysis of the National Health and Nutritional Examination Survey

Thursday, October 5, 2017 10:20-11:20 AM, 2:30-3:30PM

A Collins, J Leafman A.T. Still University

IM McFarlane, M Rodriguez Alvarez, S Zhaz Leon, DJ Ozeri, C Saladini-Aponte, T Ho Shin, Y Saperstein, M Bhamra, L Freeman, N Ojike Department of Medicine, State University of New York, Downstate Medical Center, Brooklyn, NY.

004. Obstructive sleep Apnea and Atrial Fibrillation: A Meta-Analysis

008. Multiple-Ascending-Dose Study of IW1973, a Soluble Guanylate Cyclase Stimulator

I Youssef, H Kamran, N Patel, M Yacoub, C Goulbourne, S Kumar, N Jina, BB Desulme, J Kane, SI McFarlane State University of New York Downstate Medical Center, Department of Medicine

JP Hanrahan1, J Wakefield1, P Wilson1, M Mihova1, JG Chickering1, D Ruff2, M Hall1, GT Milne1, MG Currie1, AT Profy1 1 Ironwood Pharmaceuticals, Cambridge MA. 2 ICON Early Phase Services LLC, San Antonio, TX.

005. Patiromer for Hyperkalemia Treatment in Resistant Hypertensive Patients on RAASi with Diabetic Kidney Disease

009. Health Disparities among Adult Patients with Familial Hypercholesterolemia in the CASCADE FH™ Patient Registry

Friday, October 6, 2017 9:45 – 10:45AM, 3:00-4:00PM

Thursday, October 5, 2017 10:20-11:20 AM, 2:30-3:30PM

SM Amrock1, P. B Duell 2, T Knickelbine3, SS Martin4, EC O’Brien5, KE Watson6, J Mitri7, I Kindt8, P Shrader5, SJ Baum9, LC Hemphill10, CD Ahmed8, RL Andersen11, IJ Kullo12, D McCann13, KS Sharma14, M Murray15, R Fishberg16, J Guyton17, K Wilemon8, MT Roe5, DJ Rader18, CM Ballantyne19, JA Underberg 20, P Thompson21, D Whellan22, MF Linton23, MD Shapiro24, PM Moriarty25, JW Knowles26, ZS Ahmad27 Department of Medicine, Oregon Health & Science University, Portland, OR. 2 Division of Endocrinology, Department of Medicine, Oregon Health & Science University, Portland, OR. 3 Minneapolis Heart Institute Foundation, Minneapolis, MN. 4 Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD. 5 Duke Clinical Research Institute, Durham, NC. 6 UCLA Center for Cholesterol and Lipid Management, Los Angeles, CA. 7 Joslin Diabetes Center, Harvard Medical School Boston, MA. 8 The FH Foundation, South Pasadena, CA. 9 Seth J. Baum, MD. Preventive Cardiology Inc., Boca Raton, FL. 10 Massachusetts General Hospital, Boston, MA. 11 Lancaster General Health/Penn Medicine, Lancaster, PA. 12Mayo Clinic, Rochester, MN. 13 Central Maine Heart and Vascular Institute/ Central Maine Medical Center (CMMC), Lewiston ME. 14 The Ohio State University Medical Center, Columbus OH. Karvita. 15 Precision Health Center/Genomic Medicine Institute/ Geisinger, Forty Fort PA. 16 Atlantic Health System, Springfield NJ. 17 Duke University Medical Center, Durham, NC. 18 University of Pennsylvania, Philadelphia, PA. 19 Baylor College of Medicine, Houston, TX. 20 Langone Medical Center, New York NY. 21 Hartford Hospital, Hartford CT. 22 Thomas Jefferson University, Philadelphia, PA. 23 Vanderbilt University School of Medicine, Nashville, TN. 24 Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR. 25 University of Kansas Medical Center, Kansas City, KS. 26 Division of Cardiology, Department of Medicine, Stanford University, Stanford, CA. 27 Division of Endocrinology, Department of Medicine, University of Texas Southwestern, Dallas, TX 1

*On Thursday, October 5th from 5 - 6pm, our Chairs Dr. Ballantyne, Dr. Bakris, Dr. Eckel, and Dr. Skyler will select the best poster presented during the poster session. The awarded will receive a prize of $300. This Best Poster Award is sponsored by Medical Sciences, an international open access journal providing a platform for advances in basic, translational, and clinical research.

12th Annual CMHC Accreditation ACTIVITY TITLE: 12th Annual Cardiometabolic Health Congress ACTIVITY DATE October 4-7, 2017 | Location: Boston, MA TARGET AUDIENCE The CMHC is designed for advanced level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk including cardiologists, endocrinologists, diabetologists, lipidologists, pharmacists, primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), and other allied health professionals. PROGRAM OVERVIEW The ever-increasing presence of cardiometabolic risk continues to be a major challenge for health care providers in the United States. Current estimates suggest approximately 23% - 38% of all U.S. adults have metabolic syndrome, a constellation of cardiometabolic risk factors, including excessive abdominal fat, insulin resistance, inflammation, dyslipidemia, and hypertension. Patients with multiple cardiometabolic risk factors have twice the likelihood of developing and dying from cardiovascular disease and more than seven times the risk of developing diabetes compared to those with no cardiometabolic risk factors. Cardiovascular disease already affects approximately 83.6 million U.S. adults (> 1 in 3) and is the leading cause of U.S. deaths; however, this CVD burden can be expected to increase. This sampling of sobering statistics points to a rapidly growing epidemic of cardiovascular and metabolic disease and calls to the forefront the need for medical education focused on all aspects of cardiometabolic risk. The CMHC presents an especially valuable venue for this educational outreach with sessions fostering a collaborative, multidisciplinary approach to care. The 2017 Cardiometabolic Health Congress will translate the latest cutting edge medical research into practical, clinical strategies for preventing, delaying, and managing cardiovascular and metabolic disorders. The goal is to provide the medical community with evidence based interventions to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk. EDUCATIONAL OBJECTIVES After completing this activity, the participant should be better able to: Define the interrelationships among cardiomet• abolic risk factors, their impact on cardiovascular health, and their common comorbidities Describe evidence-based guideline recommen• dations based on recent clinical trials for prevention, screening, and treatment of cardiometabolic risk factors and their comorbidities Identify treatment regimens for cardiometabolic • diseases based on efficacy and safety of current, new, and emerging pharmacotherapies, benefits of lifestyle modifications, and patient profiles and preferences to optimize patient outcomes Implement communication strategies and • patient education on new and emerging treatments, administration techniques, and technologies into clinical practice in order to promote adherence to treatment regimens FACULTY Please see Pages 8-9 to view all faculty listings and disclosures. PROGRAM AGENDA Please see Pages 6-7 to view the full agenda.

SCOPE CERTIFICATION The World Obesity/Clinical Care committee decided that the further learning value, quality and structure of the 12th Annual Cardiometabolic Health Congress comply with Specialist Certification of Obesity Professional Education (SCOPE) principles. This event has been accredited with 4 SCOPE Points which count towards SCOPE Certification. SCOPE Certification is conferred by the World Obesity Federation and is the internationally-recognized standard of excellence in obesity management. SCOPE Certification is awarded to health professionals with obesity management experience who have earned 12 SCOPE points. For questions regarding SCOPE points, please contact info@cardiometabolichealth.org. PHYSICIAN ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accre tion Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and CMHC. Global is accredited by the ACCME to provide continuing medical education for physicians. PHYSICIAN CREDIT DESIGNATION Global Education Group designates this live activity for a maximum of 28 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. NURSING CONTINUING EDUCATION Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This educational activity for 28 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity. PHARMACIST ACCREDITATION STATEMENT Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. CREDIT DESIGNATION Global Education Group designates this continuing education activity for 28 contact hour(s) (2.8 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge based activity. Universal Activity Numbers (UAN) are listed below.

Pre-Conference “Business of Medicine” Day The Patient-Centered Medical Home: A Foundation for Patient Satisfaction UAN 0530-9999-17-303-L01-P Efficient and Cost Effective Management of the Authorization Process Supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals UAN 0530-9999-17-304-L01-P Expert Discussion: The Psychology Behind Patient Adherence UAN 0530-9999-17-305-L01-P How to Grow Your Revenue By Enhancing Your Presence: In Person, On Camera & Online UAN 0530-9999-17-306-L01-P

www.CardiometabolicHealth.org

Session I. Dyslipidemia, Atherosclerosis and Cardiovascular Risk Reduction CME Breakfast Symposium: Closing the Gap Created by Clinical Inertia: New Strategies for T2DM Treatment UAN 0530-9999-17-307-L01-P FDA Update and Late Breaking Clinical Trials UAN 0530-9999-17-308-L01-P Attacking Atherothrombosis: Which Approach to Take? UAN 0530-9999-17-309-L01-P MAIN KEYNOTE: Gut Microbes as a Participant and Therapeutic Target in Cardiometabolic Diseases UAN 0530-9999-17-310-L01-P CME Lunch Symposium: Navigating Updated Guidelines and New Therapies for the Diagnosis and Treatment of Heart Failure UAN 0530-9999-17-311-L01-P Lp(a) and Promising NEW Targets for Intervention UAN 0530-9999-17-312-L01-P Treatment for Statin Intolerant Patients with Hypercholesterolemia – Today and Tomorrow UAN 0530-9999-17-313-L01-P Topic: Triglycerides and HDL-C: Where Are We Now? UAN 0530-9999-17-314-L01-P Multidisciplinary Case Consults: Challenging Lipid Cases UAN 0530-9999-17-315-L01-P CME Dinner Symposium: Advances in Insulin Therapy: Addressing Provider and Patient Safety Concerns UAN 0530-9999-17-316-L01-P Session II. Lifestyle Management of Cardiovascular Disease CME Breakfast Symposium: Interventional Cardiology Delivered With a Fork UAN 0530-9999-17-317-L01-P Ensuring Access to Evidence-Based Therapies in High Risk Special Populations: Statin Intolerance, Racial/ Ethnic Minorities and Familial Hypercholesterolemia UAN 0530-9999-17-318-L01-P Topic: Novel Mechanisms for the Link Between Obesity and Type 2 Diabetes UAN 0530-9999-17-319-L01-P Cardiometabolic Disorders: Diet Quality, Quantity and Beyond UAN 0530-9999-17-320-L01-P Sleep Science: Effect of the Circadian Rhythm on Obesity and CVD UAN 0530-9999-17-321-L01-P Multidisciplinary Case Consults: Lifestyle and Obesity Management in the Cardiometabolic Patient UAN 0530-9999-17-322-L01-P CME Lunch Symposium: CV Protection: Is It Achievable in Patients with T2DM? UAN 0530-9999-17-323-L01-P Session III. Diabetes Management New Insights Into Insulin Resistance and How the Body Responds to It UAN 0530-9999-17-324-L01-P Reaching Glycemic Goals for Patients with T2DM: Insulin and Non-Insulin Therapies UAN 0530-9999-17-325-L01-P Managing Microvascular Complications of Diabetes for Improved Patient Outcomes UAN 0530-9999-17-326-L01-P Multidisciplinary Case Consults: Challenging T2DM Patient Cases UAN 0530-9999-17-327-L01-P Session IV. Hypertension, Cardio-Renal, Heart Failure CME Breakfast Symposium: Hyperkalemia Management and Monitoring in High-Risk Patients: Improving Heart Failure Management and Outcomes UAN 0530-9999-17-328-L01-P Topic: Metabolomics and Kidney Disease UAN 0530-9999-17-329-L01-P

2017 Guideline Updates: Blood Pressure and Resistant Hypertension UAN 0530-9999-17-330-L01-P Integrative Topics in Blood Pressure and Hypertension Management UAN 0530-9999-17-331-L01-P Multidisciplinary Case Consults: Challenging Patient Cases in Hypertension, Cardio-Renal, and Heart Failure UAN 0530-9999-17-332-L01-P Kidney Disease in the Elderly UAN 0530-9999-17-333-L01-P

DIETICIAN ACCREDITATION STATEMENT Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 28 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012 GLOBAL CONTACT INFORMATION For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@ globaleducationgroup.com.

INSTRUCTIONS TO RECEIVE CREDIT

In order to obtain your CME/CE credits for the CMHC, please complete the steps below: Post-conference: You will receive an email containing a link to complete your CMHC Program Evaluation by approximately Monday, October 9, 2017. Online evaluations must be completed by October 31, 2017. CME/CE Certificates will be available for print immediately upon completion of the online evaluation form. Pharmacists Only: In order to receive credit, the ACPE requires that you provide your NABP ePID (6-10 digits) along with month and date of birth (MMDD) in the online evaluation. After completion of the evaluation via steps outlined above, record of your participation will be uploaded to the CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed before December 4, 2017. FEE INFORMATION & REFUND/CANCELLATION POLICY There is registration fee for this educational activity, registration information can be found https://www.cardiometabolichealth.org/2017/register-12th-annual.html DISCLOSURE OF CONFLICTS OF INTEREST Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Name of Planner or Manager Ashley Marostica, RN, MSN Lindsay Borvansky Andrea Funk Erin Franceschini, MS Amanda Jamrogiewicz Karin McAdams Reported Financial Relationship Nothing to disclose The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Christie M. Ballantyne, MD Grant/Research Support (all significant, all paid to institution, not individual): Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, NIH, AHA, ADA Consultant/Independent Contractor: Abbott Diagnostics, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc., Merck, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo George L. Bakris, MD Consultant/Independent Contractor: Janssen, Relypsa, AbbVie, Merck, Boehringer-Ingelheim, Sanofi, Pfizer Robert H. Eckel, MD Consultant/Independent Contractor: Sanofi/Regeneron-Expert Witness Jay S. Skyler, MD Consultant/Independent Contractor: Adocia, AstraZeneca, BD, Boehringer Ingelheim/Eli Lilly Collaboration, Dance Biopharm, DiaVacs, Elcelyx Therapeutics, Genentech, Immnomolecular Therapeutics, Intarcia Therapeutics, Intrexon, Merck, Orgenesis, Sanofi Diabetes, Servier, vTv Therapeutics (Trans Tech), Valeritas Grant/Research Support: Mesoblast, Viacyte Ownership Interest/Shareholder: Dance Biopharm, DexCom, Inc., Elizabeth Therapeutics, Ideal Life, Intrexon, Moerae Matrix, Orgenesis, Paean Therapeutics, SynAlpha Therapeutics, VasoPrep Surgical Board of Directors Member: DexCom, Inc., Elizabeth Therapeutics, Moerae Matrix, Paean Therapeutics, SynAlpha, VasoPrep Surgical. Scientific Advisory Board Member: Adocia, Intarcia Therapeutics, Intrexon, Sanofi Diabetes, Viacyte Other/Royalty: Dexcom Inc., Intarcia Therapeutics, Sanofi Diabetes Catherine Davis Ahmed, MBA Ms. Ahmed has nothing to disclose. Jamy D. Ard, MD Dr. Ard has no relevant personal relationship(s) to disclose. Deepak L. Bhatt, MD, MPH Grant/Research Support: Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi Aventis, The Medicines Company Kim K. Birtcher, PharmD Dr. Birtcher has nothing to disclose. Eugene Braunwald, MD Grant/Research Support: Merck David A. Calhoun, MD Consultant/Independent Contractor: Valencia Technologies Grant/Research Support: Medtronic, ReCOR

Janet M. de Jesus, MS, RD Ms. de Jesus has nothing to disclose. Stephen Devries, MD, FACC Dr. Devries has nothing to disclose. Keith C. Ferdinand, MD, FACC, FAHA Consultant/Independent Contractor: Quantum Genomics, Novartis, Amgen, Sanofi, Eli Lilly Grant/Research Support: Boehringer Ingelheim John P. Foreyt, PhD Dr. Foreyt has nothing to disclose. Roy Freeman, MD Received personal compensation for serving on scientific advisory boards of: Acetylon, Astellas, Biogen, Daiichi-Sankyo, Grace, Insys, Lundbeck, Nestle, Novartis, Pfizer, Vertex and Spinifex. Thomas W. Gardner, MD, MS Dr. Gardner has nothing to disclose. Paul Grundy, MD, MPH, FACOEM, FACPM Dr. Grundy has nothing to disclose. Yehuda Handelsman, MD Grant/Research Support: Amgen, AstraZeneca, BMS, BI, Grifols, Janssen, Lexicon, Merck, Novo Nordisk, Sanofi. Advisory/Consultant: Amarin, Amgen, AstraZeneca, BI, Eisai, Intarcia, Lilly, Janssen, Merck, Merck-Pfizer, Novo Nordisk, Regeneron, Sanofi. Speakers Bureau: Amarin, Amgen, AstraZeneca, BI-Lilly, Janssen, Merck, Novo Nordisk, Sanofi, Regeneron. Dr. Handelsman and his immediate family do not have ownership interest and/or stocks of any Pharmaceutical or device company. David G. Harrison, MD, FACC, FAHA Dr. Harrison has nothing to disclose. Stanley L. Hazen, MD, PhD Consultant/Independent Contractor: Esperion, Proctor & Gamble Grant/Research Support: Proctor & Gamble, AstraZeneca, Pfizer, Roche Diagnostics, Takeda Honoraria: National Academy of Sciences; AHA Scientific Sessions; various academic institutions Other/Royalty: Cleveland Heart Lab, Frantz Biomarkers, Siemens Robert John Hughes Mr. Hughes has nothing to disclose. Barbara Kahn, MD Consultant/Independent Contractor: Alterna Grant/Research Support: Janssen Other/Royalty: Janssen Scientific Advisory Board C. Ronald Kahn, MD Consultant/Independent Contractor: Merck, CohBar, MedImmune Stock Shareholder: Kaliedo Biosciences, Antriabio, CohBar Grant/Research Support: MedImmune Davida F. Kruger, MSN, APNBC, BCADM Advisory Boards: Novo Nordisk, Abbott, Eli Lilly and Company, Sanofi Aventis, Janssen Speakers Bureau: Janssen, Valeritas, AstraZeneca, BI/ Lilly, Novo Nordisk, Dexcom Grants/Research Support to Henry Ford Health System: AstraZeneca, Eli Lilly, Novo Nordisk, Hemsley Foundation, Dexcom, Lexicon Stock: Dexcom Wendy S. Lane, MD Consultant/Independent Contractor: Novo Nordisk, Intarcia, Insulet Grant/Research Support: Novo Nordisk, Eli Lilly, Lexicon Pharmaceuticals, Mylan Honoraria: Novo Nordisk, Insulet Speakers Bureau: Novo Nordisk, Insulet JoAnn Lindenfeld, MD Consultant/Independent Contractor: Relypsa, VWare, Abbott, Novartis, Edwards, Cariomic Grant/Research Support: Novartis, AstraZeneca

Pamela B. Morris, MD Consultant/Independent Contractor: Amgen, SanofiRegeneron, AstraZeneca Anne L. Peters, MD Consultant/Independent Contractor: Abbott Diabetes Care, Becton Dickinson, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Lexicon, Medscape, Merck, Novo Nordisk, Omada Health, OptumRx, Perrigo, Roche, sanofi Grant/Research Support: Dexcom Speaker’s Bureau: Abbott Diabetes Care, Becton Dickinson, Boehringer Ingelheim, Eli Lilly and Company, Janssen Other/Royalty: Editorial Fee: Medscape Athena Philis-Tsimikas, MD Consultant/Independent Contractor: Advisory board on behalf of Scripps Health for Astra Zeneca, DexCom, Lilly, Novo Nordisk, Sanofi (no direct or indirect reimbursement to advisor) Grant/Research Support: Janssen, Lilly, Novo Nordisk, Sanofi, (No direct or indirect reimbursement to researcher) Stock Shareholder: Ionis, Gilead, Novo Nordisk, Esperion William H. Polonsky, PhD, CDE Consultant/Independent Contractor: Lilly, Sanofi, Novo, Intarcia, Dexcom, Abbott, Roche, AstraZeneca, MannKind Grant/Research Support: Merck Paul M. Ridker, MD Grant/Research Support: Dr Ridker reports having received research funding support from multiple notfor-profit entities including the National Heart, Lung, and Blood Institute, the National Cancer Institute, the American Heart Association, the Doris Duke Charitable Foundation, the Leducq Foundation, the Donald W Reynolds Foundation, and the James and Polly Annenberg La Vea Charitable Trusts. Dr Ridker also reports having received investigator-initiated research support from Astra-Zeneca, Novartis, Pfizer, and Kawa, as well as non-financial research support from Amgen. Other/Royalty: Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease that have been licensed to Siemens and AstraZeneca, and has served during the past year as a research consultant to Sanofi, Quintiles, AstraZeneca, and TEVA. Julio Rosenstock, MD Consultant/Independent Contractor: I have served on scientific advisory boards and received honorarium or consulting fees from the following: Roche, Sanofi, Novo Nordisk, Eli Lilly, Daiichi Sankyo, AstraZeneca, Janssen, Boehringer-Ingelheim, Lexicon, and Intarcia Grant/Research Support: Merck, Pfizer, Sanofi, Novo Nordisk, Roche, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Takeda, AstraZeneca, Janssen, Daiichi Sankyo, Lexicon, Boehringer-Ingelheim, and Intarcia Marc S. Sabatine, MD, MPH Consultant/Independent Contractor: Amgen; CVS Caremark; Esperion; Ionis; MedImmune; Merck (all ≤$10,000 per year except Amgen, Esperion, and Ionis) Grant/Research Support: Research grant support through Brigham and Women’s Hospital from: Amgen; AstraZeneca; Daiichi-Sankyo; Eisai; GlaxoSmithKline; Intarcia; Janssen Research Development; MedImmune; Merck; Novartis; Pfizer; Poxel; Takeda Johannes Scholl, MD Dr. med. Johannes Scholl has nothing to disclose. Frank A.J.L. Scheer, PhD Honoraria: Speaker fees from Bayer Healthcare and Sentara Healthcare

Benjamin M. Scirica, MD, MPH Grant/Research Support: Dr. Scirica reports research grants via the TIMI Study and Brigham and Women’s Hospital from AstraZeneca, Eisai, and Poxel. Consultant/Independent Contractor: AstraZeneca, Biogen Idec, Boehringer Ingelheim, Covance, Dr. Reddy’s Laboratory, Elsevier Practice Update Cardiology, GlaxoSmithKline, Lexicon, Merck, Novo Nordisk, Sanofi, St. Jude’s Medical, and equity in Health [at] Scale. Kumar Sharma, MD Grant/Research Support: Boehringer Ingelheim, Merck Virend K. Somers, MD, PhD Consultant/Independent Contractor: GlaxoSmithKline, Dane Garvin, Biosense Webster, Respicardia, Philips, Rhonda Grey, Bayer, U-Health, ResMed, Piper Jaffray. Grant/Research Support: Philips Respironies, NIH Grants Mark J. Tager, MD Dr. Tager has nothing to disclose. Sotirios Tsimikas, MD Consultant/Independent Contractor: Ionis Pharmaceuticals, Inc. Grant/Research Support: NIH, Regeneron Stock Shareholder: Ionis Pharmaceuticals, Inc. Other/Royalty: UCSD patent Clyde W. Yancy, MD, MSc, MACP Dr. Yancy has nothing to disclose.

DISCLOSURE OF UNLABELED USE This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and CMHC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Educational Grant Support The 2017 Cardiometabolic Health Congress general sessions are supported in part by an independent and unrestricted educational grant from Pfizer. JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

www.CardiometabolicHealth.org

The Cardiometabolic Event of the Yearâ&#x201E;˘

SAVE THE DATE

2018

OCTOBER 24 â&#x20AC;&#x201C; 27 BOSTON, MA The largest multidisclipinary conference of its kind, CMHC provides a unique opportunity to learn the latest scientific and clinical developments in the overlapping areas of cardiovascular and metabolic disease.

Visit CMHC registration or visit our booth #20 in the Exhibit Hall

www.cardiometabolichealth.org *Offer valid for 2018 Annual Congress only. Must be engaged in clinical practice and not employed by a pharmaceutical, medical device, medical education/advertising agency, or similar company to be eligible for the physician or allied health professional discounted registration fees.

ABOUT US Advancing Education in Cardiometabolic Disease

OUR HISTORY

WEIGHT MANAGEMENT AGE, RACE, SEX, GENETICS, FAMILY HISTORY D • CAR

BEHAVIORAL, LIFESTYLE CHOICES

ETA B OLIC H

LT H

ETA B O LIC

LT H

OM EA

DYSLIPIDEMIA

•C

I ARD

HYPERTENSION CARDI0-RENAL SYNDROME HEART FAILURE PRIMARY AND SECONDARY CVD RISK INSULIN RESISTANCE, PREDIABETES, DIABETES

The Cardiometabolic Health Congress (CMHC) is more than an annual conference or regional meeting. CMHC provides a single point of access for busy practitioners to stay abreast of evolving science, clinical practice advances and continuing education in cardiometabolic disease prevention and management. CMHC provides a complete platform of education spanning live and digital communications that extends the energy and experience of our national and regional conferences throughout the year and to a wider audience of frontline clinicians with an interest in cardiometabolic health. With more than one-third of the population having at least one cardiometabolic risk factor - dyslipidemia, CHD, hypertension, diabetes and/or obesity - CMHC provides a one-of-a-kind opportunity for busy

clinicians to catch up on the latest developments in these overlapping areas of cardiometabolic health. With no board certification, graduate or medical school training formally recognized in Cardiometabolic Science and Medicine, and continuing education that is delivered in specialty specific silos, CMHC provides an integrated and comprehensive solution. CMHC has a decade of history bringing together experts across the spectrum of diabetes, obesity, and cardiovascular disease to share ideas and foster collaborations. The curriculum is at the cutting edge of science, translating the latest research to practical approaches for the entire multidisciplinary health care team. CMHC offers live conferences and online educational programs.

Cardiometabolic Health Congress launched in October 2006 in Boston and has grown to be the largest US-based, multidisciplinary conference addressing cardiometabolic disease prevention and its interdependencies through an integrated approach to education. CMHC Boston is held each October and attended by 1,300+ multidisciplinary health professionals seeking real-world solutions to integrate directly into their clinical practices. In 2015, CMHC expanded to include the CMHC Regional Conference Series: Focus on Frontline Education held in cities across the US, as well as CMHC West: Advancing Cardiometabolic Health from East to West.

The Cardiometabolic Health Congress is produced by Tarsus®. The acquisition of the CMHC in early 2014 expanded Tarsus’ medical division, Tarsus Medical Group, to include live and online medical education offerings focused on the prevention and management of cardiometabolic diseases. Tarsus Medical Group provides a comprehensive, revolutionary collection of global events focused on valuable live and online medical education programs for healthcare practitioners of various specialties. All entities are geared at providing clinical education focused on disease prevention and management, taking into account a rapidly changing health industry. A division of Tarsus Medical owned by Tarsus PLC

2018 A D VA N C I N G C A R D I O M E TA B O L I C H E A LT H F R O M E A S T TO W E S T

MAY 4–5 | LAS VEGAS, NV

Register On-Site for ONLY $99 More than one-third of the population has at least one cardiometabolic risk factor - dyslipidemia, CVD, hypertension, diabetes, and/or obesity. The

Session topics include • CVD PREVENTION • DIABETES

Cardiometabolic Health Congress is the largest,

• DYSLIPIDEMIA

US-based, multidisciplinary conference focused

• HYPERTENSION

solely on the management of cardiometabolic risk and the prevention of cardiovascular and metabolic disease. www.cardiometabolichealth.org

Visit CMHC registration or visit our booth #20 in the Exhibit Hall

• OBESITY